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1. INTRODUCTION 
 
1.1 Male infertility 
Human infertility is an emotionally charged problem affecting an estimated 15 % of all couples. It is 
defined as the inability to conceive within 12 months or longer (1). The man should be evaluated 
concurrently with the woman, since the male factor is the primary or contributing cause in 
approximately 40 % to 50 % of cases (1, 2). Thus, half of all cases of infertility can be attributed in 
part or completely to the male factor. 
Fertility in men requires normal spermatogenesis, sperm transport, and accessory gland function. 
Hence, the causes for male infertility are diverse and are linked to e.g. hormonal imbalance, congenital 
abnormalities such as cryptorchidism, infections, antispermatogenic agents and sexual dysfunction (3). 
A general decrease of male fertility during the last decades has been reported and might be due to 
harmful environmental influences, stress and pollutants (4). Commonly, when it comes to diagnose 
male infertility, the analysis of the semen is the most obvious way to evaluate the man (2). A semen 
analysis allows determining sperm concentration, motility and morphology (World Health 
Organization 2003 (204)). Nevertheless, it is only a surrogate marker to assess male fertility because 
approximately 15 % of patients with male factor infertility have normal semen (5). In these cases other 
tests, such as hormone assessment, genetic studies and testicular biopsies, are necessary. The latter is 
needed to evaluate spermatogenesis in patients with potential genital tract obstructions. A high 
proportion of men with genital tract obstructions suffer from severe spermatogenic disorders (6). 
These cases of spermatogenesis failures reach from moderate to severe hypospermatogenesis. For 
instance, testes of men with germ cell arrest (GA) possess cellular components for functional 
spermatogenesis, but at a certain stage the process is interrupted and no functional spermatozoa are 
produced (3, 7). A further important testicular disease diagnosed in infertile men is the Sertoli cell-
only (SCO) syndrome, where tubules contain Sertoli cells but no germ cells (3). Sub- or infertile men 
can also be diagnosed with mixed atrophy (MA), which is characterized by tubules with various 
degrees of degeneration of the germinal epithelium within the same biopsy. Seminiferous tubules, in 
which all germ and Sertoli cells have disappeared and only thickened walls are left, can occur in close 
proximity to normal tubules (8). 
Although infertility in men can result from several reasons, it is an important fact, that in 
approximately 40 % to 50 % of all cases no specific etiologic cause can be defined and a full 
understanding of male infertility in these cases remains elusive (3). 
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1.2 Testicular morphology 
The testis is a complex organ of the male reproductive system. Healthy male mammals possess two 
ellipsoid shaped testes. In healthy adult men average testicular volume is 15 – 30 ml and normal testis 
size is approximately 3.5 – 5.5 cm in length and 2.0 – 3.0 cm in width (9). 
The two major functions of the testis are the production of hormones and spermatozoa. The testicular 
capsule, the tunica albuginea, consists of tight connective tissue and represents the outermost layer of 
the testis. Fibrous septa originate from the tunica albuginea and divide the organ into about 250 
compartments, the so-called lobuli testes. Each lobuli testes contains 1 – 4 strongly coiled tubuli 
seminiferi, in which developing germ cells and Sertoli cells are located. The seminiferous tubules are 
surrounded by loose connective tissue containing Leydig cells, peritubular myoid cells, blood and 
lymphatic vessels, immune cells and neurons. The average diameter of the seminiferous tubule in 
sexual mature human testis is 150 – 250 µm. Seminiferous tubules are 30 – 70 cm in length and at the 
end of each tubule, the lumen narrows and continues in tubil recti, that connect the seminiferous 
tubules to the rete testis. Via ductuli efferentes the rete testis is connected to the epididymis (10). The 
seminiferous tubular compartment of the human testis occupies about 90 % of the organ volume (11). 
 
 
1.3 Testicular cytoarchitecture and function 
In adult mammals the testis comprises two structurally distinct but functionally connected 
compartments: the tubular seminiferous epithelium and the interstitial compartment between the 
seminiferous tubules (Figure 1-1). These two compartments fulfill the main functions of the testis: 
interstitial cells secrete testicular androgens, while seminiferous tubules produce male germ cells.  
 
Seminiferous epithelium 
The seminiferous epithelium contains Sertoli and germ cells. The latter occur at different 
developmental stages within the seminiferous epithelium. Ultrastructural examination of the human 
seminiferous epithelium has shown that the arrangement of germ cells is highly organized into a 
helical patterns based upon the geometry of concentric spirals (12). Spermatogonia, which represent a 
primitive stage of germ cell, are located in the basal compartment (Figure 1-1). After the onset of 
sexual maturity spermatogonia develop, during a complex process called spermatogenesis, to mature 
spermatozoa. Spermatogenesis begins with a series of mitoses in the spermatogonium and the newly 
formed cells can continue as stem cells for the spermatogenic lineage, type A spermatogonia, or as 
progenitor cells, type B spermatogonia. The latter differentiates into primary spermatocytes which 
undergo the first meiotic division, a process that results in secondary spermatocytes. Secondary 
spermatocytes occupy positions closer to the lumen of the tubule and quickly enter into the second 
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meiotic division that results in spermatides. During spermiogenesis, spermatides differentiate to 
spermatozoa. Finally, mature spermatozoa are released to the lumen of the seminiferous tubule, which 
ends in the rete testis and leads to the epididymis. The whole process of spermatogenesis lasts 
approximately 70 days (3, 10). 
 
Sertoli cells provide structural and functional support to developing germ cells and extend from the 
basal lamina to the lumen of the seminiferous tubule and partially envelop germ cells (Figure 1-1) (9). 
They are characterized by their polar, elongated shape and their elongated, folded or indented nucleus 
(10, 12, 13). In adult human testis Sertoli cells continuously produce and secrete a fluid into the lumen 
of the seminiferous tubule, a process that is androgen-dependent. This fluid contains various factors to 
nourish germ cells, as well as, to support spermatogenesis and is responsible for the transport of sperm 
within the seminiferous tubule (3, 10).  
In the basal part of the seminiferous tubule, adjacent Sertoli cells form tight junctions and constitute 
the so-called blood-testis barrier, which divides the seminiferous tubule into basal and adluminal 
compartements. The blood-testis barrier prevents large molecules, steroids and ions to pass from the 
blood into the lumen of the seminiferous tubule and thus creates a protected environment within the 
tubule to support spermatogenesis. In this way, the more advanced stages of spermatogenesis are 
protected against toxic agents transported by blood to the testis and furthermore against an auto-
immune reaction caused by arising sperm proteins during puberty (10). During the reproductive period 
human Sertoli cells do not divide. Therefore they are extremely resistant to infections, malnutrition, 
and x-ray irraditation. 
 
Figure 1-1: Diagram of the testicular compartments. A part of a seminiferous tubule and 
surrounding interstitial is shown. This figure was modified after Juniqueira et al., 2005 (10). 
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Interstitial tissue 
The interstitial compartment in human testes is located between the seminiferous tubules and contains 
connective tissue, neurons, blood and lymphatic vessels, immune cells, peritubular myoid cells and 
Leydig cells. Adult Leydig cells are characterized by their round or polygonal shape and their ovoid 
nucleus with a prominent nucleolus. In a process called steroidogenesis, Leydig cells produce steroids, 
primarily testosterone, which are important for an efficient spermatogenesis and furthermore are 
responsible for developing secondary male sex characteristics (10, 12, 13). 
As Leydig cells and interstitial fibroblasts, peritubular myoid cells are derived from mesenchymal 
cells. In the interstitial compartment they surround the seminiferous epithelium and are in contact with 
the basal surface of Sertoli cells (Figure 1-1). Because of their contractile phenotype, peritubular 
myoid cells are essentially involved in the transport of spermatozoa and testicular fluid through the 
seminiferous tubules (14).  
A further interstitial component of the testis is the extensive extracellular matrix (ECM), which 
provides structural integrity of the testis. Numerous ECM components, including fibronectin, laminin, 
collagens type I and IV and proteoglycans, are produced and secreted by Sertoli cells, peritubular 
myoid cells and Leydig cells. Sertoli cells and peritubular myoid cells cooperate to form the basal 
lamina of the seminiferous tubules. The ECM is able to affect peritubular myoid and Sertoli cell 
functions and therefore plays an important role in male reproductive health (13, 14).  
 
 
1.4 Regulation of testicular function 
Spermatogenesis is a complex process, depending on hormones secreted by the hypothalamus, 
hormone gonadotropin-releasing hormone (GnRH), and hormones secreted by the pituitary gland, 
namely luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The appropriate regulation 
of androgen activity via this hypothalamic-pituitary-testicular axis is necessary for developing male 
phenotype characteristics, as well as for the initiation and maintenance of spermatogenesis (10).  
LH stimulates Leydig cell steroidogenesis, a process in which androgens, especially testosterone, are 
synthesized. Stimulation of the androgen pathways occurs mainly through cyclic adenosine 
monophosphate (cAMP) mediated mechanisms, including LH induced guanyl nucleotide binding, 
membrane phosphorylation and adenylat cyclase activation. Activation of cAMP dependent kinase 
likely leads to phosphorylation of proteins of the steroidogenic pathway and subsequently testosterone 
production is increased (15).  
FSH acts on the seminiferous epithelium, in particular on Sertoli cells. Under FSH/testosterone control 
Sertoli cells secrete androgen-binding protein that serves to concentrate testosterone in the 
seminiferous tubule. Testosterone is essential for the initiation and maintenance of spermatogenesis 
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and therefore fertility, but how it exerts this effect is not completely clear (16, 17). Receptors for 
testosterone, androgen receptors (ARs), are expressed in Sertoli cells, germ cells and peritubular 
myoid cells. Continuing uncertainty exists over which cell type mediates testosterone control over 
spermatogenesis, but it has been shown in mouse testis that germ cells lacking the AR mature 
normally (18). Therefore testosterone is believed to regulate spermatogenesis via somatic cells in the 
testis. In mouse studies the importance of androgen action on peritubular myoid cells for normal 
spermatogenesis has been shown (19). 
The factors produced by testicular cells do not only influence the testis itself but also affect some 
extratesticular functions. Testosterone, for example, can affect secondary sex characteristics. It 
influences hair growth, skin, muscle and male accessory sex organs (10).  
Estrogens are required for a normal testicular function, as well. Reports of testicular anomalies in men 
with naturally occurring mutations in the aromatase gene and of rodents lacking a functional estrogen 
receptor alpha (ER-α) support the view that estrogens are essential in human male differentiation, 
spermatogenesis and steroidogenesis (20-22).  
 
Testicular functions are known to be primarily regulated by endocrine mechanisms via LH and FSH. 
However, the proximity of different cell types in the testis, as well as a number of regulatory factors 
produced intratesticularly, strongly suggest a role of paracrine regulation in testicular function (23-25). 
For example, intratesticular produced growth factors have been shown to influence proliferation and 
biological function of various human testicular cells (26). Among these growth factors, epidermal 
growth factor (EGF), a cytokine that promotes cell proliferation, regulates tissue differentiation, and 
modulates organogenesis in several species (27, 28), has been described. In the human testis the 
receptor for EGF (EGFR) has been detected in Leydig and peritubular myoid cells, but not in Sertoli 
and germ cells (26). Very few studies have dealt with EGF/EGFR signaling in the human testis, but in 
rat it was reported to be involved in testis development and spermatogenesis (28). 
A further important growth factor system has been identified in the testis, namely platelet-derived 
growth factor (PDGF) and its receptors PDGFR-α and -β. In rodents, PDGF was reported to play 
important roles in testis development and the regulation of spermatogenesis (29, 30). Furthermore, it 
has been shown, that PDGF enhances testosterone production by adult rat Leydig cells (31) and 
stimulates proliferation of peritubular myoid cells (32). PDGF and PDGFRs have been reported to be 
expressed in the human testis possibly could affect testis developmental processes, spermatogenesis 
and male infertility (33). 
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1.5 Peritubular myoid cells 
Peritubular cells, which are of particular interest in the present study, have been described for the first 
time in 1901 by Regaud (34) who observed a single layer of flattened cells surrounding the 
seminiferous tubule in the rat testis. Electron microscopic studies of the peritubular connective tissue 
in human testis by Ross and Long in 1966 (35) revealed the presence of “contractile-type” cells. 
Similar to smooth muscle cells, cytoplasmic filaments, cell surface invaginations and centrally located 
organelles were found in peritubular cells. These cytological resemblances to smooth muscle cells 
finally lead to the name “peritubular myoid cells” (36). Because of their contractility, peritubular 
myoid cells play an important role in the transport of the spermatozoa within the lumen of the 
seminiferous tubule. It has been shown that several substances, e.g. prostaglandins, Tumor growth 
factor beta (TGF-β) and endothelin, can affect the contractions of the seminiferous tubules (14). 
Ultrastructural analysis showed that cytoplasmatic filaments within the peritubular myoid cells are 
expressed and distributed in a species-specific manner (14, 37). Among actin isoforms, alpha-smooth 
muscle actin (α-SMA) occurs only in myoid and vascular smooth muscle cells and in no other rat cell 
type (38). In the monkey α-SMA is used as specific marker for testicular peritubular myoid cells (39). 
In addition to actin, peritubular myoid cells of several species, including the human, were shown to 
also contain myosin and intermediate filaments (40).  
The number of cell layers surrounding the seminiferous tubule varies from species to species (41). 
While in rodents (rat, mouse, hamster) peritubular myoid cells form a single flat layer, multiple (five 
till seven) layers exist in humans. In the human testis each layer is separated by laminae of 
extracellular connective tissue. Species-specific differences also exist in the degree of differentiation 
from fibroblasts to smooth muscle cells in the myoid cell population. In humans the one or two 
outermost layers of peritubular cells are regarded to be fibroblasts and the inner layers are thought to 
be smooth muscle cells (42). 
In addition to their role in contraction of the seminiferous tubules, peritubular myoid cells are able to 
synthesize numerous substances. Among those are components of the ECM, including fibronectin, 
type I and IV collagens and proteoglycans. In cooperation with Sertoli cells, that produce laminin, 
type IV collagen and proteoglycans, peritubular myoid cells form the basal lamina of the seminiferous 
tubules (14, 43).  
Previous studies indicated that peritubular myoid cells in rodents via their secreted products can 
contribute directly or indirectly to spermatogenesis and testicular development. They possess the 
ability to secrete factors such as PModS (peritubular cell factor that modulates Sertoli cell activity in 
rodents (44)), or growth factors like TGF-α (45), TGF-β (46), insulin-like growth factor 1 (IGF-1) 
(47), activin-A (48) and fibroblast growth factor (FGF) (49). Thus, human peritubular myoid cells may 
as well affect adjacent testicular cell types via secreted factors and thus have regulatory functions in 
spermatogenesis and testis development. 
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1.6 Testicular fibrosis, mast cells and macrophages 
Fibrosis is a pathological event that occurs in many organs of the body, e.g. the lung, liver, kidney, 
heart and skin, and is characterized by increased fibroblast numbers and accumulation of ECM 
proteins (50-52). 
In the human testis, various forms of hypospermatogensis are accompanied by fibrotic thickening of 
the wall of the seminiferous tubules (53). As mentioned above, increased levels of ECM components 
are produced under these pathological conditions and lead to fibrotic remodeling of the tubular wall 
which is a typical event associated with male infertility (3). While the average thickness of the 
peritubular wall in normal testis is 7 – 9 µm, in patients with disturbed spermatogenesis it is increased 
to 12 – 20 µm (42, 54). However, regardless of the varying thickness of the ECM, the number of 
cellular layers surrounding the seminiferous tubule remains constant (42). The reasons for the fibrotic 
changes in the testis and their consequences for male infertility are not clear, but it has been speculated 
that the thickened testicular peritubular wall could disturb the exchange of fluid between the tubular 
compartment and the interstitial compartment (55). 
Interestingly, several studies showed that fibrotic changes in the testis and testicular dysfunction 
correlate with increased numbers of testicular immune cells (54, 56-62). In the healthy human testis, 
mast cells, macrophages and leukocytes occur, and are located mainly to the interstitial compartment 
(63, 64). Normally, testicular mast cells are characterized by their round phenotype and besides their 
occurrence in the interstitial compartment, about 13 % of total mast cells can be detected in the 
peritubular region (54). In infertile men, suffering from GA or SCO syndrome, a two respectively 
three times higher testicular mast cell number than in normal testis was found. Another striking 
difference to normal testis was reported: more mast cells are located in the peritubular wall of infertile 
men. In testes of GA and SCO patients, 19 % respectively 26 % of total testicular mast cells were 
located in the peritubular region. The phenotype of mast cells in the testis of infertile men is altered as 
well. Mast cells of men with impaired spermatogenesis are heterogeneous, with an irregular, round or 
elongated shape and show signs of activation and degranulation. Interestingly, the thickness of the 
fibrotic remodeled tubular wall in infertile men coincides with the number of activated mast cells (54). 
This important finding raised the question how increased numbers of activated testicular mast cells 
can be linked to sub-/infertility. Several studies showed that mast cells, in general, are able to secrete 
various products, including histamine, serotonin, growth factors, prostaglandins, cytokines and 
proteases (62, 65-67). In rodents, testicular mast cell products (e.g serotonin or histamin) that could be 
involved in regulation of testicular steroidogenesis have been identified (68, 69). Human testicular 
mast cells secrete mainly histamine, chymase and tryptase (54, 57, 70). The serine protease tryptase 
has been shown to activate the protease-activated receptor (PAR)-2 (59, 71), a process that leads to 
fibroblast proliferation (66, 72, 73). Furthermore, PAR-2 activation by tryptase can stimulate synthesis 
of type I collagen (74, 75) and enhance fibroblast chemotaxis (59). 
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The observation that mast cell numbers are increased in testis of men with spermatogenesis defects, 
especially in the peritubular region, led to the suggestion that mast cells via tryptase could be directly 
responsible for the development of testicular fibrosis in infertility patients (54, 57). 
 
Morphological studies revealed that testicular macrophages are located in the interstitial compartment 
and occasionally in the peritubular region and inside the lumen of seminiferous tubules of the normal 
human testis (58, 64, 76). Because of their ability to produce and secrete some inflammatory 
cytokines, e.g. interleukin 1 alpha (IL-1α), interleukin 1 beta (IL-1β) and tumor necrosis factor alpha 
(TNF-α) (77, 78), testicular macrophages play a potential role in paracrine interactions with other 
testicular cell types (58, 79). 
Surprisingly, in the testis of men suffering from infertility the total number of macrophages is 
increased in comparison to normal testis (58). A two times higher macrophage number has been 
detected in GA and SCO syndrome patients. In MA patients the number of total macrophages is not 
altered, but the number of peritubular and intratubular macrophages is higher than in fertile men. In all 
pathologic states, a shift of macrophages from the interstitial compartment to the lumen of the tubules 
has been observed (58). These increased macrophage numbers in the testes with hypospermatogonism 
or complete absence of germ cells led to the suggestion that macrophages via their secretory products 
could contribute to the formation of male infertility. 
It has been shown that mast cells and macrophages can interact with each other. This interaction leads 
to proliferation of fibroblasts and formation of collagen in some tissues (80, 81). The close anatomic 
proximity between macrophages and mast cells in the testicular interstitial area and in the wall of 
seminiferous tubules has been described and therefore an interaction between testicular mast cell and 
macrophages, that causes fibroblast proliferation and collagen formation and leads to testicular 
fibrosis, could be assumed (72). It remains unknown, what induces the fibrotic remodeling, called a 
hallmark of human male infertility (3), but mast cells and macrophages via their direct and indirect 
products may be involved. 
 
 
1.7 The proteoglycan decorin 
The components of the ECM of the human testis and their specific functions are not well known, but 
different collagen types, fibronectin, laminin (42, 82-88) and the proteoglycans, decorin (DCN) and 
biglycan (89) have been identified. 
The first time that DCN, originally called PG40, appears in the literature is in 1986, when Krusius and 
Ruoslahti (90) described a small chondroitin/dermatan sulfate proteoglycan with a molecular weight 
of 40 kDa, which was expressed by human fibroblasts. DCN, whose name has derived from its 
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morphological nature to decorate collagen fibers in vivo (91), turned out to be a widely distributed 
component of the ECM.  Besides its structural functions to regulate collagen fibrillogenesis, DCN 
might play an important regulatory role because of its ability to bind other ECM proteins, growth 
factors and growth factor receptors (92-94).  
DCN is the prototype member of an expanding gene family of secreted proteoglycans called the small 
leucine-rich proteoglycans (SLRPs). The SLRPs share the unique structural motif of leucine-rich 
tandem repeats that are responsible for most of their biological functions (95). The family of SLRPs 
contains at least nine different members, including DCN, biglycan, lumican, proline-arginine-rich and 
leucine-rich repeat protein, keratocan, fibromodulin, lumican, epiphycan, and osteglycin, which are 
encoded by separate genes (96). The distribution of SLRPs among species and throughout evolution 
reflects a diversity of biological functions. Initially thought to act exclusively as structural constitutes 
and regulators of collagen fibrillogenesis, SLRPs are nowadays recognized as key players in cell 
signaling. They are able to influence cell proliferation, differentiation, survival, adhesion, migration 
and inflammatory responses (97-99). 
The best-known and most studied members of the SLRP family are DCN and biglycan. Despite their 
structural similarity (55 % amino acid identity), DCN and biglycan show distinct patterns of temporal 
and spatial expression, indicating their different biological functions (100). 
With regard to structural characteristics, DCN originally was divided into four distinct domains 
(Figure 1-2) (96). Domain I contains a signal peptide and a propeptide. The biological role of the 
propeptid is still unclear, but it may function as a recognition signal for the first enzyme, 
xylosyltransferase, involved in the synthesis of glycosaminoglycan (GAG) chains (101). The second 
structural domain of DCN is a negatively charged region, which contains four cysteine residues and 
one GAG chain. The central structural region, domain III, contains ten tandem leucine-rich repeats and 
is responsible for binding collagen type I (102, 103). It has been reported that besides collagen type I, 
DCN can also bind collagen type II (104), type III (105), and type VI (106). The fourth domain of the 
DCN molecule, the carboxyl end, contains a relatively large loop with two cysteine residues.  
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Figure 1-2: Diagram of the structural characteristics of DCN. The structure of the 
prototype member of the small leucine-rich proteoglycans can be diveided in four 
distinct domains (I-IV). SP: signal peptide, PP: propeptide, Cys: cysteine-rich region, 
LRR: leucine-rich repeat. This figure was modified after Iozzo, 1998 (96). 
 
 
The DCN gene maps to the chromosome 12 (12q23) in humans (107), and to chromosome 10 in mice 
(108). The human DCN gene is encoded by eight distinct exons. The intron/exon junctions are highly 
conserved with nearly identical exon organization in the human and murine DCN. The human DCN 
gene harbors two leader exons (Ia and Ib) that are alternatively spliced to exon II (107), whereas the 
murine gene does not contain exon Ib (108). The promoter region of DCN is functional active (109) 
and contains two functional TNF-α-responsive elements that mediate a TNF-α-induced transcriptional 
repression of the DCN gene (110). It has been shown that DCN expression can be induced by IL-1 
(111) or by IL-4 (112). In contrast, DCN is downregulated by TGF-β (109). 
Computer modeling suggested that the human DCN core protein is arch shaped with a single GAG 
chain and three N-linked oligosaccharides located on the same side of the molecule. The leucine-rich 
repeats form a central cavity with the β-sheet on the inner concave surface and the α-helices on the 
outer convex surface (113). In the past it was assumed that the inner concave surface is able to bind 
one collagen molecule (113), but recent studies suggest that the protein core of one DCN molecule 
interacts with four to six collagen molecules (114). 
The binding of DCN to fibrillar collagen (Figure 1-3) has important biological consequences in vivo, 
as has been shown by the DCN knock out mouse model. The disruption of the DCN gene in these 
mice lead to skin fragility with markedly reduced tensile strength and abnormal collagen morphology, 
characterized by uncontrolled lateral fusion of collagen fibrils (115).  
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Figure 1-3: Electron micrographic view of DCN precipitates in the 
peritubular wall of human testis. Fine and distinct Cupromeronic 
blue precipitates (small black needles), representing DCN, 
interconnect adjacent collagen fibrils. Longitudinal and cross sections 
through collagen fibrils are shown. The length of the bar is 
approximately 0.1 µm. Electron micrographic picture was done 
by Prof. Dr. Dr. U. Welsch. 
 
 
In addition to collagen fibrillogenesis, two other actions of DCN have been recognized, linking DCN 
to fundamental biological processes, including cell migration, adhesion and proliferation (116, 117). 
First, within the interstitial ECM, DCN binds a variety of soluble and insoluble ligands, thus 
regulating their availability and activity. This is well documented for TGF-β (118, 119) and PDGF 
(117). Second, DCN itself can act as a non-selective ligand for several growth factor receptors, 
including EGFR (120, 121), insulin-like growth factor 1 receptor (IGF-1R) (120-122), vascular 
endothelial growth factor receptor (VEGFR) (123) and hepatocyte growth factor receptor (HGFR) 
(124). It appears that DCN may cause initial activation of the respective signaling pathway, followed 
by its inactivation, as shown for example for EGFR (125). In tumor cells the binding of DCN to the 
EGFR leads to growth suppression by activation of the mitogen-activated protein kinase (MAPK)-
pathway, calcium (Ca2+) influx, induction of the cyclin-dependent kinase inhibitor p21, and 
subsequently down-regulation of the receptor (125-130).  
In 1995 DCN was described for the first time in the healthy human testis (89). It has been reported that 
DCN gene expression is located to single, dispersed fibroblastic cells in the interstitial compartment, 
as well as to the adventitious layer of ateries and to cells of the peritubular wall. The possible role of 
DCN in the testis has not been investigated. 
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1.8 The cellular model 
In the past very few studies dealt with human peritubular cell cultures (37, 131). Testicular tissue was 
obtained from prepubertal patients and enzymatic digestion methods have been used to isolate 
peritubular cells and investigate their temporarily steroidogenic potential (37). Another study showed 
the expression pattern of intergrins in human peritubular myoid cells as well as their role of the 
inhibition of contractility in rat and human pertitubular myoid cells (131). 
A few years ago the successful isolation and cultivation of human testicular peritubular cells (HTPCs) 
(55) opened the door to the investigation of this unexplored testicular cell type and its involvement in 
paracrine mechanisms in the adult human testis in vitro. Peritubular cells were cultured from explants 
from testicular biopsies obtained from men undergoing reconstructive surgery for obstructive 
azoospermia but displaying normal spermatogenesis (for details see 2.1 and 3.1.1). Morphologically, 
HTPCs are characterized by their elongated, myofibroblast-like appearance. As they have been shown 
to be immunonegative for FSH and LH receptors, contaminations with Sertoli or Leydig cells can be 
excluded (55, 132).  
The origin of isolated HTPCs from the peritubular region was proven in vivo and in vitro by 
immunostaining with fibroblast markers (CD90/THY1) and the smooth muscle cell marker, α-SMA 
(55). Furthermore the expression of ECM genes and genes coding for basement membrane 
components, such as collagen type I, IV and XVIII, fibronectin and laminin, by HTPCs was shown 
(55). Cultivated HTPCs express functional receptors for the immune cell products histamine (H1), 
tryptase (PAR-2) and the cytokine TNF-α (TNFR1 and -2) (55, 132, 133). The secretory character of 
these cells was identified and secreted products such as nerve growth factor (NGF), monocyte 
chemoattractant protein (MCP-1), prostaglandins, IL-6 and glial cell line derived growth factor 
(GDNF) were detected (132, 133). 
Recently the isolation of HTPC-Fs, the corresponding cells from testes of men with existing fibrotic 
changes and spermatogenesis defects, was described (132). The reported loss of contractility markers 
and hypertrophy in cultured peritubular cells of men with impaired spermatogenesis indicates a switch 
of the phenotype of peritubular cells from a contractile to a synthesizing cell type (134).  
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1.9 The AROM+ mouse 
Aromatization of androgens is a key step in estrogen production in the gonads (135). The enzyme 
aromatase is responsible for this process. With regard to male reproductive functions, the 
estrogen/androgen ratio in the testis is of particular interest (21). To study the important regulation of 
the balance between estrogen/androgen in the testis, transgenic mice expressing human P450 
aromatase under the human ubiquitin C promoter were generated (AROM+) (135). While AROM+ 
females are unaffected, AROM+ males are characterized by an imbalance in intratesticular sex 
hormone metabolism, resulting in elevated serum estradiol and prolactin concentrations, combined 
with significantly reduced testosterone and FSH levels. The mice suffer from structural and functional 
alterations in the reproductive organs, including cryptorchidism, Leydig cell hyperplasia, and impaired 
spermatogenesis. Furthermore, the AROM+ males develop rhabdosphincter atrophy and rudimentary 
sex glands (136). 
Old male AROM+ mice (15 months) develop Leydig cell hypertrophy and adenoma (137). Chronic 
inflammation, characterized by an increased number of activated, TNF-α producing, macrophages in 
the testicular interstitial region of aging AROM+ mice, has been reported. The increased activity of 
the macrophages is associated with Leydig cell depletion and an increased number of mast cells and 
fibroblasts in the interstitial compartment. Interestingly, similar findings have been made in testes of 
infertile men (54).  
 
 
1.10 Aims of the study 
Impaired spermatogenesis in men is frequently accompanied by accumulation of testicular immune 
cells and by fibrotic remodeling of the walls of the seminiferous tubules. Surprisingly little is known 
about this remodeling process that is associated with male infertility, but striking alterations of the 
cellular components of the testicular peritubular wall and of the ECM are evident. The expression and 
the role of ECM proteoglycans, such as DCN, in the testis has not been studied yet. Because studies in 
other organs have shown that DCN acts as a ligand of growth factor receptors or can store growth 
factors, similar interactions with growth factor signaling might play a role in the testis in health and 
disease. 
In order to examine this hypothesis, the present study investigates DCN expression sites in the human, 
non-human primate (rhesus monkey) and mouse testes. To gain further insights in DCN expression in 
pathologically altered testis, human samples of MA, GA and SCO syndrome patients and samples of a 
transgenic mouse model (AROM+) were investigated. AROM+ males are characterized by infertility 
and a high amount of activated macrophages, infiltrating mast cells and interstitial fibrosis in the testis 
and thus are an appropriate model for the study of inflammation-associated male infertility. Finally, 
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expression of DCN during testicular development was studied in the non-human primate, using 
testicular samples of rhesus monkeys of different ages.  
Having established strong expression of DCN in the human testicular peritubular compartment, cells 
of this region were further examined with respect to regulation and action of DCN. DCN regulation 
and function in the human testis in health and disease were examined using primary HTPCs, which 
stem from testes with normal spermatogenesis and from men suffering from spermatogenic failure and 
fibrotically altered tubular walls (HTPC-Fs). Testicular factors known to play important roles in male 
reproductive health, were investigated for their ability to regulate DCN. The expression of growth 
factor receptors in HTPCs and HTPC-Fs was examined and the ability of DCN to interact with growth 
factor signaling, especially with EGF and PDGF, was studied. 
Since strong DCN expression was found in testes of AROM+ males, primary mouse testicular 
fibroblasts were isolated to further examine DCN regulation in this cell type. 
In additional experiments, the action of the cancer drug imatinib mesylate, an exogenous ligand to 
growth factor receptors, on viability of HTPCs and its interaction with PDGF signaling in these cells 
were studied.    
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2. MATERIAL 
 
2.1 Human biopsies 
Human testicular tissue used in this study was obtained by open biopsy carried out by Prof. Dr. J. U. 
Schwarzer (Praxis Urology-Andrology, Freising, Germany) or Prof. Dr. F. M. Köhn (Andrologicum, 
Munich, Germany). Testicular biopsies were isolated from vasectomized men with obstructive 
azoospermia undergoing reconstructive surgery but displaying normal spermatogenesis. Furthermore, 
biopsies were obtained from patients with spermatogenesis defects and fibrosis in the wall of the 
seminiferous tubules. In these cases of sub-/infertility, men are suffering from different testicular 
disorders, including MA, GA or SCO syndrome. The ages of the patients in this study range between 
27 and 53 years. All participants granted written informed consent. The ethics committee of the 
Technical University in Munich approved the study.  
 
 
2.2 Transgenic mice expressing human P450 aromatase 
In this study the AROM+ mouse model was used (135-137). Generation of transgenic male mice 
expressing human aromatase complementary deoxyribonucleic acid (cDNA) under the control of 
ubiquitin C promotor (AROM+ mice) was carried out by Dr. Leena Strauss (Department of 
Physiology and Turku Center for Disease Modeling, Institute of Biomedicine, University of Turku, 
Finland). The mice were fed with Soya free diet, and they were maintained in a specific pathogen-free 
stage at Central Animal Laboratory at the University of Turku, complying with international 
guidelines on the care and use of laboratory animals. All animal experiments were approved by the 
Finnish Animal Ethics Committee.  
The AROM+ mice were generated in FVB/N genetic background (135). For genotyping of the mice, 
polymerase chain reaction (PCR) analyses were performed using DNA extracted from tail biopsies. 
Genotyping was carried out by Dr. Leena Strauss as described by Li et al. in 2001 (135).  
Testicular samples from at least three young (3 – 5 months of age) and old adult (9 – 10 months of 
age) AROM+ and age-matched wild type (WT) males were fixed in Bouin’s solution, embedded in 
paraffin and 5 µm-thick sections for immunohistochemistry were prepared (137). Freshly isolated 
testes of AROM+ and wild type mice of different ages (2 weeks till 9 months) were used for cell 
culture experiments. In addition, testes from at least three young and three old wild type and AROM+ 
mice were frozen and kept until isolation of ribonucleic acid (RNA). 
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2.3 Rhesus monkey testicular samples 
Testes from rhesus monkeys (Macaca mulatta) that were primarily involved in other unrelated studies 
(138) were obtained through the Oregon National Primate Research Center (ONPRC) Tissue 
Distribution Program by Prof. Dr. Henryk F. Urbanski and Vasilios T. Garyfallou. The animals were 
cared for by the ONPRC in accordance with the National Research Council’s Guide for the Care and 
Use of Laboratory Animals. They were classified as: infantile (0 - 1 year; n = 4), juvenile (1 - 2 years; 
n = 1), peripubertal (3 - 4 years; n = 2), young adult (5 - 6 years; n = 3) and old adult (24 - 30 years;    
n = 5).  
For the purpose of this study, the testes were isolated and were fixed for at least 48 h in Bouin’s 
solution, followed by 70 % ethanol, and then embedded in paraffin. Sections (5 µm) were prepared for 
immunohistochemistry experiments. 
 
 
2.4 Other materials 
All chemicals, kits and assays, antibodies, machines and laboratory materials, used in this study, are 
listened in the APPENDIX (table 10-1 till 10-6). An overview about composition of all buffers and 
solutions employed is given in the APPENDIX (table 10-7).   
 
 
  17 
3. METHODS 
 
3.1 Cell culture 
3.1.1 Isolation and cultivation of HTPC/-Fs 
HTPC and HTPC-Fs were isolated as described by Albrecht et al. in 2006 (55). Immediately after 
removal, the testis tissue was transferred to Dublecco`s modified Eagle`s medium (DMEM)/Ham´s 
F12 medium containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.5 g/l 
sodium bicarbonate, 15 % fetal calf serum (FCS), 100 U/ml penicillin, and 100 µg/ml streptomycin. 
Under sterile conditions the testicular tissue covered with medium was dissected into small pieces     
(1 – 2 mm3) using forceps and scalpel. Drops (approximately 10 µl) of human plasma supplemented 
with calcium chloride (1 mM) were placed on a 60-mm plastic culture dish and the tissue samples 
were placed in these drops to adhere the testicular explants to the surface of the culture dish. Small 
drops of medium were placed between the tissue samples to assure sufficient humidity. The explants 
were incubated over night at 37 °C, 5 % CO2 and 95 % humidity, and subsequently checked for 
adherence. The adherent explants were cultured in medium composed as described above. After about 
one week the cell outgrowth started and tissue pieces were carefully removed. When the cells have 
grown to confluence they were trypsinized and subcultured adding 1.5 ml trypsin-ethylene-
diaminetetraacetic acid (EDTA) for 4 min. The reaction was stopped adding 3 ml DMEM 
supplemented with 10 % FCS and centrifuging the cell suspension at 1,000 revolutions per minute 
(rpm). HTPCs and HTPC-Fs were cultured in DMEM supplemented with 10 % FCS unless indicated 
otherwise.  
Before the cells were used for further investigations, every sample was tested for mycoplasma 
contamination using a commercial mycoplasma detecting kit for conventional PCR according to the 
manufacturer`s protocol. Cells from passages 2 – 15 were used freshly or cryopreserved for all 
experiments. Cyropreservation in 1.6 ml cryocups was performed using DMEM (high Glucose 4.5 
g/L; with L-Glutamine and Phenol Red) containing 10 % FCS and 5 % dimethylsulfidoxide (DMSO).  
 
3.1.2 Isolation of mouse testicular fibroblasts 
At first, mouse testicular peritubular cells were isolated and cultivated using the explant method 
described for HTPCs above. Three different media were used for this approach. Immediately after 
removal, one group of mouse testicular samples was transferred to the medium as used for cultivating 
HTPCs (DMEM/Ham`s F12 medium containing 20 mM HEPES, 0.5 g/l sodium bicarbonate, 15 % 
FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin), another group into Roswell Park Memorial 
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Institute (RPMI) 1640 medium (Ready mix with L-Glutamine, Phenol Red and 10 % FCS) and a third 
group of testicular samples was transferred into a smooth muscle cell-specific growth medium. Under 
sterile conditions the testes covered with medium were decapsulated and dissected into small pieces             
(1 – 2 mm3). Afterwards the samples were processed as described for human samples.  
In about 70 % of cultures with fibroblast growth medium and about 40 % of cultures with RPMI cell 
outgrowth started from few explants after about five days. The cells grew very slowly to confluence 
and when they were trypsinized for subculturing, a high death rate could be observed. No cell growth 
could be observed in samples cultured with DMEM/Ham´s F12. Mice of different ages, from two 
weeks till five months, were used for cell isolation experiments, but cell growth could not be 
improved. 
Since mouse peritubular cells, using the explant method did not grow well, mouse testicular 
fibroblasts from the interstitial region were isolated by collagenase digestion. Testes were removed 
from 4 – 10 months old animals and collected in DMEM supplemented with 10 % FCS, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. The tunica albuginea and as much of the vascular tissue as 
possible were removed. The tissue was transferred into fresh medium and was minced in a petri dish 
under sterile conditions. The tissue fragments were treated with a solution of  collagenase I (200 U/ml) 
in DMEM with 10 % FCS. During incubation in a water bath at 37 °C for 1 h 30 min, the samples 
were gently vortexed every 10 min. After this digestion procedure the epithelial cell fraction was 
allowed to sediment for 2 min. The supernatant, containing the fibroblasts, was transferred to a new 
tube and centrifuged at 800 rpm for 3 min. Afterwards it was washed twice with phosphate buffered 
saline (PBS). The cell pellet was resolved in DMEM (supplemented with 10 % FCS, 100 U/ml 
penicillin and 100 µg/ml) and seeded on 60 mm plastic culture dishes. The number of culture dishes 
depended on the size of the cell pellet. Usually six dishes per animal were obtained. The cells were 
incubated over night at 37 °C, 5 % CO2 and 95 % humidity, subsequently checked for adherence and 
washed twice with DMEM.  
 
3.1.3 NIH/3T3 cells 
NIH/3T3 (3-day transfer, inoculum 3 x 105) cells, standard mouse fibroblasts, were used for initial 
studies in mice. Originally, this cell line was established from primary mouse embryonic cells (139). 
The cells were cultured in DMEM supplemented with 10 % FCS and were incubated in a 5 % CO2 
atmosphere at 37 °C and 95 % humidity.  
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3.1.4 Cell treatment 
It was assumed that substances, which are known to play important regulatory roles in the testis, might 
affect DCN gene expression in the peritubular wall. The regulation of DCN expression in the nearly 
unexplored cellular models HTPC and HTPC-Fs was investigated performing an initial screening by 
challenging respectively both cell types with several substances as stated below.  
Testosterone is the main regulating androgen produced by the testis. Therefore, HTPC/-Fs which 
possess AR (unpublished data), were challenged with testosterone. A concentration of 100 nM for a 
time period of 24 h was used. Testosterone was dissolved in 100 % ethanol and used at a 1:1000 
dilution. Since the estrogen/androgen level plays a significant role in male reproductive health (135), 
peritubular cells of healthy testis and cells of testis of infertile men were treated with 17β-estradiol 
(concentrations: 100 nM and 1 µM; dissolved in 100 % ethanol and diluted 1:1000 and 1:100) for 6 h 
and 24 h. While in these first experiments steroid hormones, which are important regulators of 
testicular functions under normal physiological conditions, were used, additionally substances known 
to play a role in pathologically altered testis were tested on DCN regulation. For instance the 
prostaglandin D2 system is of special relevance in testis of infertile men (134, 140). Thus HTPC/-F, 
that express receptors for protsglandin D2, were treated with 15-deoxy-Δ12-14-Prostagladin-J2 
(15dPGJ2; 10 µM) for 7 days. 15dPGJ2 was dissolved in 100 % ethanol and used at a 1:1000 dilution. 
Forskolin is a diterpene commonly used to raise cAMP levels. Since stimulation of the androgen 
pathways occurs mainly through cAMP mediated mechanisms, e.g. adenylate cyclase activation (15), 
forskolin was also used in this study for cell stimulation. HTPCs and HTPC-Fs were treated with      
50 nM forskolin for 4 h. Forkolin was dissolved in 100 % ethanol and used at a 1:200 dilution. 
Mast cells and macrophages are present in increased numbers in fibrotic remodeled testis (54, 58). 
Their main secreted products, besides histamin, TNF-α and tryptase were used to challenge HTPCs as 
well as HTPC-Fs. Cell treatment was performed with human recombinant TNF-α (dissolved in H2O 
and diluted 1:1000 to a final concentration of 5 ng/ml), human recombinant rhSkin β tryptase 
(dissolved in H2O and diluted 1:1000 to a final concentration of 100 ng/ml) and PAR-2 agonist peptide 
SLIGKV (dissolved in H2O and diluted 1:1000 to a final concentration of 10 µM) for two different 
time points, 24 and 72 h.  
Solvents for all substances were included as controls. Reagents and solvents are summarized in table 
3-1. The respective reagent or solvent was added to the culture medium (DMEM supplemented with 
10 % FCS) and cells were incubated at 37 °C, 5 % CO2 and 95 % humidity. Cell treatment was 
followed by isolation of RNA or protein. Supernatants were collected for enzyme-linked 
immunosorbent assay (ELISA) experiments.  
NIH/3T3 cells were treated with mouse TNF-α (dissolved in H2O and diluted 1:1000 to a final 
concentration of 5 ng/ml) for 24 and 72 h. TNF-α was added to the culture medium (DMEM 
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supplemented with 10 % FCS) and cells were incubated at 37 °C, 5 % CO2 and 95 % humidity. 
Solvents were included as controls for each time period. Cell treatment was followed by RNA and 
protein isolation. 
In addition to DCN regulation, the actions of DCN in HTPCs and HTPC-Fs were investigated. In 
initial experiments, cells were cultivated in presence of different concentrations of human recombinant 
or bovine articular cartilage DCN (1, 10 and 20 µg/ml) and acute Ca2+ signals or levels of adenosine 
triphosphate (ATP) levels after 24 h were measured. As 10 µg/ml of DCN proved to be effective, this 
concentration was used for further investigations. DCN was dissolved in H2O and diluted 1:200 to a 
final concentration of 10 µg/ml. No difference in the ability of the DCN preparation to mobilize 
intracellular Ca2+ or to change cell viability was observed. Subsequently, unless indicated otherwise, 
bovine DCN was generally used, but for each experiment human recombinant DCN was tested, as 
well.  
As DCN is known to be able to interact with growth factor signaling, this possibility was investigated 
by treating HTPC/-Fs with different concentrations of human recombinant EGF and human 
recombinant PDGF-BB for different time points and ATP measurements, measurements with an 
automated cell counting device (CASY) and 4′, 6′-diamidino-2′-phenylindole (DAPI) experiments 
were performed after cell stimulation. EGF was dissolved in H2O and diluted 1:1000 to a final 
concentration of 50 ng/ml. PDGF-BB isoform was used because it is known to bind all PDGFR 
isoforms and dimerizes α- and β-receptors into different configurations (PDGFR-αα, -αβ, -ββ) (29). 
PDGF-BB was dissolved in 4mM HCl containing 0.1 % BSA and was used at a 1:1000 dilution         
(5 ng/ml). Details of cell treatment are described for every single experiment below.  
In addition to DCN actions, the influence of the cancer drug imatinib mesylate on growth factor 
signaling in HTPCs was investigated in this study. Imatinib mesylate (originally called STI571; Glivec 
or Gleevec, Novartis Pharma, Basel, Switzerland) is a chemotherapeutic agent employed to treat 
patients with chronic myeloid leukemia (141). Imatinib specifically inhibits Abelson tyrosine kinase, 
an abnormal tyrosine kinase resulting from the Philadelphia chromosome, which is constitutively 
expressed in chronic myeloid leukemia (141). The imatinib concentrations required for inhibition of 
the Abelson tyrosine kinase also inhibit other receptor tyrosine kinases (RTKs), including c-kit and 
PDGFR (142-144). In the developing rat testis, c-kit and PDGF/PDGFR signaling pathways play 
essential roles in the development and migration of Leydig cells and peritubular myoid cells, and 
proliferation and survival of spermatogonia (145). Cells of both groups were treated with different 
concentrations (10, 20, 50 or 100 µM) for 1 or 4 days of imatinib mesylate and/or 5 ng/ml PDGF-BB. 
Subsequent experiments, such as measuring of ATP levels and DAPI experiments, were performed as 
detailed below. Cells, treated with solvents, were included as controls. Reagents and their solvents 
used for cell treatment are summarized in table 3-1 and cell stimulation details are described for each 
single experiment below. 
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Table 3-1: Summary of reagents and their solvents. 
 
Substance Solvents (stock) 
DCN PBS 
15dPGJ2 100 % Ethanol 
17β-Estradiol 100 % Ethanol 
EGF H2O 
Forskolin 100 % Ethanol 
Imatinib mesylate H2O 
PDGF-AA H2O 
PDGF-BB 4 mM HCl + 0.1 % BSA 
Testosterone 100 % Ethanol 
Human recombinant TNF-α H2O 
Mouse recombinant TNF-α H2O 
Human recombinant tryptase  H2O 
SLIGKV H2O 
 
 
3.2 Molecular biology 
3.2.1 RNA-Isolation 
The cells were grown to subconfluence and incubated with/without stimulant in DMEM containing  
10 % FCS for different time points. Subsequently, the cells were washed twice with DMEM without 
FCS and suspended in 600 µl RLT-buffer containing 1 % β-mercaptoethanol. Tissue of human 
testicular biopsies was homogenized in 600 µl RLT-buffer containing 1 % β-mercaptoethanol using an 
Ultrathurax. RNA-isolation was performed at room temperature using a QIAGEN RNeasy minikit. 
Each cell/tissue lysate was passed five times through a cannula and transferred directly into a spin 
column placed in a 2 ml collection tube. Samples were centrifuged at 10,000 rpm for 30 sec. The flow 
through was resuspended in 600 µl ethanol (70 %) and transferred to a RNeasy spin column placed in 
a 2 ml collection tube. Samples were centrifuged at 10,000 rpm for 15 sec. The flow-through was 
discarded and several washing steps were performed (700 µl RW1 buffer, 2 x 500 µl RPE buffer). The 
RNA was eluted using 30 µl RNase-free water and RNA content and quality were determined by 
measuring the absorbance of an 1:30 RNA:RNase-free water solution at 260 nm in a biophotometer. 
The RNA samples were stored at -80 °C until reverse transcription was performed.  
RNA of frozen or freshly removed WT/AROM+ mouse testis was isolated using a different method. 
Samples were homogenized in 1 ml TRIsure reagent using an Ultrathurax and subsequently incubated 
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for 5 min at room temperature. 200 µl chloroform were added and samples were shaken by hand for 
15 sec. After incubation for 3 min at room temperature, samples were centrifuged at 10,000 rpm for  
15 min at 2-8 °C. The colorless upper aqueous phase was transferred into a fresh tube and the RNA 
was precipitated by mixing with 500 µl isopropyl alcohol. Samples were incubated for 10 min at room 
temperature, followed by centrifugation at 10,000 rpm for 10 min at 2-8 °C. The pellet was washed 
with 1 ml ethanol (75 %), vortexed, centrifuged at 7,000 rpm for 5 min at 2-8 °C and air-dried for     
10 min. Finally the RNA pellet was dissolved in diethylpyrocarbonate- (DEPC-) treated water by 
incubating for 10 min at 60 °C in a thermomixer.  
The RNA concentration was determined measuring 1 µl RNA sample in a NanoDrop. To check RNA 
quality gel electrophoresis using a 1 % tris base/boric acid/EDTA- (TBE-) buffered agarose gel and    
1 µg of each sample was performed. Agarose gel electrophoresis is described in detail below. 
To eliminate contaminating DNA during RNA purification a Deoxyribonuclease I Amplification 
Grade Kit was used. Duplicate RNase-free, 0.5 ml microcentrifuge tubes for positive and negative 
reverse transcriptase samples were prepared. The experiment was performed on ice. The reagents for 
the amplification reaction are listed in table 3-2. After incubation for 15 min at room temperature, 1 µl 
of 25 mM EDTA solution was added to the samples to inactivate DNase I. After an incubation step at 
65 °C for 10 min, the samples were ready for reverse transcription. 
 
 
Table 3-2: Summary of reagents and their volumes used for amplification.  
 
Reagent Volume 
RNA sample (1 µg) 0-8 µl 
10 x DNase I Reaction Buffer 1 µl 
DNase I, Amp Grade 1 U/µl 1 µl 
DEPC-treated water 0-8 µl 
Total volume 10 µl 
 
 
3.2.2 Reverse transcription polymerase chain reaction 
Reverse transcription polymerase chain reaction (PCR) was used to transcribe single-stranded RNA 
into double-stranded DNA. Concerning HTPC/-Fs and mouse testicular fibroblasts, the cDNA 
template was produced using 1.6 µl of random 15-mer primer and 400 ng of total RNA. DEPC-treated 
water was added to a total volume of 23 µl. All working steps were performed on ice. Samples were 
incubated in a thermocycler for 10 min at 70 °C and afterwards 5 min at 25 °C. Subsequently 15 µl of 
master mix, containing 5 x first strand buffer, 0.1 M dithiothreitol (DTT), deoxynucleoside 
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triphosphates (dNTPs) and RNasin (40 U/µl; RNase Block Ribonuclease Inhibitor), was added. 
Details for master mix reagents see table 3-3. Samples were incubated for 10 min at 25 °C and 
subsequently for 2 min at 42 °C, before 2 µl Superscript II 200 U/µl) were added. The total volume of 
the RT-PCR was 40 µl. The program for reverse transcription see table 3-4. 
 
 
Table 3-3:  Mastermix composition for reverse 
transcription PCR with 15-mer primers. 
 
Reagent Volume 
5 x first strand buffer    8 µl 
DTT 0.1 M    4 µl 
dNTP mix 10 mM    2 µl 
RNasin 40 U/µl    1 µl 
Table 3-4: Temperatures and time periods  
for reverse transcription. 
 
Temperature (°C)   Time (min) 
      42         50 
      70         15 
       4         10 
 
 
At the Institute of Biomedicine, University of Turku, a different RT-PCR method than described 
above was used. The RNA template was produced using 1.0 µl random hexamer primers (300 ng/µl), 
10 µl 2 x buffer, 2 µl M-Mul VRT RNase and 0.5 µg of total RNA. DEPC-treated water was added to 
a total volume of 20 µl (details for mastermix see table 3-5). All working steps were performed on ice. 
The program for reverse transcription see table 3-6. 
 
 
Table 3-5: Mastermix compostition for reverse 
transcription PCR with hexamer primers. 
 
Reagent Volume 
Buffer 10 µl 
Hexamer Primer 1 µl 
RNase 2 µl 
RNA template (0.5 µg) 0 – 7 µl 
DEPC-treated water 0 – 7 µl 
Total volume 20 µl 
 
Table 3-6: Summary of temperatures and  
time periods for reverse transcription. 
 
Temperature (°C)    Time (min) 
       25         10 
       37         30 
       85           5 
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3.2.3 Semi-quantitative real-time PCR 
Real-time (RT-) PCR was used to amplify specific genes (146) and was performed using 1 µl of 
cDNA in a total reaction volume of 50 µl. Mastermix ingredients and volumes are summarized in table 
3-7. To exclude contamination by genomic DNA, negative controls using 1 µl RNA of each sample 
were performed. All pipetting steps were performed on ice. PCR conditions are listed in table 3-8.  
 
Table 3-7: Mixture for one PCR reaction. 
 
Reagent Volume 
5x GoTaq-Buffer      10 µl 
dNTPs (2 mM)        5 µl 
Primer forward (50 pmol/µl)        1 µl 
Primer reverse (50 pmol/µl)        1 µl 
GoTaq-Polymerase   0.25 µl 
DEPC-treated water 31.75 µl 
cDNA template        1 µl 
Total volume      50 µl 
 
 
Table 3-8: Real-time PCR program. 
 
Step Temperature (°C) Time 
Initialization 95 2 min 
Denaturation 95 1 min 
Annealing Primer-specific annealing temperature 30 sec 
Elongation 72 1 min 
Final elongation 72 5 min 
Final hold 4  
 
 
All PCR primers used were designed using the open source program Primer 3 (version 0.4.0; 
http://frodo.wi.mit.edu/primer3/). Purified and lyophilized primers were purchased at metabion 
international AG, Martinsried, Germany. Information about primer sequences, annealing temperatures 
and product sizes are summarized in table 10-1 (see APPENDIX 10.1).  
Amplified PCR products were visualized and identified by agarose gel electrophoresis, described 
below. To verify their identity, PCR products were purified using the QIAGEN MinElute® PCR 
Purification Kit and sequenced by GATC-biotech Konstanz, Germany. Results of sequencing were 
analysed using BLAST software (basic local alignment search tool; www.ncbi.nlm. 
nih.gov/projects/gemone/seq/BlastGen).  
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3.2.4 Quantitative real-time PCR (qRT-PCR) 
QRT-PCR studies were carried out at the Department of Physiology and Turku Center for Disease 
Modeling, Institute of Biomedicine, University of Turku, Finland. Synthesis of cDNAs for qRT-PCR 
was performed employing a DyNAmo two-step SYBR Green qRT-PCR kit and an Engine Opticon 
system for continuous fluorescent detection. For each set of conditions samples were analyzed in 
triplicates. A mastermix of 10 µl SYBR Green and 1 µl forward and 1 µl reverse primer (10 pmol/µl) 
per sample was prepared.  8 µl of cDNA (diluted 1:50) were used. In initial experiments annealing 
temperatures were determined by running gradient PCRs, analyzing the expression levels at different 
annealing temperatures from 55-61 °C. DEPC-treated water was used as negative control in each 
experiment. Table 3-9 shows the detailed program used for qRT-PCR. 
The expression levels in human cDNA samples were determined in proportion to the human ribosomal 
protein L19 (RLP19) housekeeping gene. For mouse samples the mouse RPL19 was used as 
housekeeping gene. Primer sequences and specific annealing temperatures are summarized in table 10-
1 (see APPENDIX 10.1) 
 
Table 3-9: Summary of qRT-PCR conditions. 
 
Temperature (°C) Time 
95 15 min 
94 10 sec 
Primer-specific annealing temperature 30 sec 
72 30 sec 
78 1 sec 
Read Plate, go to step 2 
72 10 min 
Melting curve from 72-95 Read every 0.5 °C, hold 1 sec 
72 5 min 
 
 
3.2.5 Agarose gel electrophoresis 
PCR products were visualized by ethidium bromide staining in TBE-buffered agarose gels (2 %). To 
detect the size of the DNA fragment a 100 bp DNA ladder was used. Electrophoresis was performed at 
90 V for 30 min. PCR fragments were visualized by ultraviolet light and evaluated densitometrically 
using ImageJ Software (version 1.40g; National Institutes of Health, Bethesda, MD, USA). The 
intensity of each sample was normalized to values obtained for cyclophilin housekeeping gene within 
the respective sample. 
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3.3 Protein biochemistry 
3.3.1 Protein extraction and measurement of protein content 
Protein was extracted either from human testicular biopsies or from cultured cells (HTPC/-Fs and 
NIH/3T3 cells) grown to confluence on 60-mm dishes. The whole preparation was performed on ice to 
avoid protein denaturation. Testis tissue was homogenized in 1.5 ml Sodiumchloride/ Pipes/EDTA-
(NPE-) buffer using an Ultrathurax. HTPC/-Fs and NIH/3T3 cells were initially washed twice with 
DMEM without additives to remove FCS. Subsequently, 1.5 ml NPE-buffer were added and cells 
were scraped off the plate and transferred to a 1.5 ml Eppendorf cup. The samples, homogenized in 
NPE-buffer, were centrifuged at 4 °C and 10,000 rpm for 3 min and afterwards the buffer was 
removed. The cell/tissue pellet was resuspended in 1.5 ml PBS and centrifuged again. Subsequently, 
50 or 100 µl inhibitor cocktail, depending on the size of the pellet, were added to each sample and 
cells were treated with ultrasonic sound for about 10 sec.  
To determine the concentration of the solubilized protein in each sample, a colorimetric DC Protein 
Assay based on the method of Lowry (147), was performed. A working reagent was prepared by 
adding 20 µl of reagent S to each ml of reagent A used. 5 µl of standards (0 – 2.0 µg/µl) and samples 
were pipetted in duplicates a clear 96-well microplate. 25 µl working solution and 200 µl of reagent B 
were added to each well and the plate was incubated for 15 min at room temperature. The absorption 
of standards and samples was measured at 750 nm in a microplate reader. Values were compared to a 
standard curve to determine the protein content. Finally 10 % β-mercaptoethanol and 10 % 
bromphenol blue were added to each sample. Samples were incubated for 5 min at 95 °C in a 
thermomixer before they were directly used in Western blot experiments or frozen at -20 °C. 
 
3.3.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to separate 
proteins according to their molecular weight. Two gels of different acrylamide contents, a loading and 
a separating gel, were used. A loading gel of 4 % acrylamide has been used for all experiments. The 
acrylamide content of the separating gel varied depending on the molecular weight of the investigated 
protein. For example, for detecting DCN protein with a molecular weight of approximately 40 kDa a 
12.5 % acrylamide gel was used, whereas phospho-EGFR and phospho-PDGFR with molecular 
weights of approximately 180 and 150 kDa were analysed on a 7.5 % acrylamide gel. 
First the separating gel (7.5 % or 12.5 % acrylamide) was poured, covered with a thin layer of 
isopropyl alcohol and allowed to polymerize for about 30 min. Thereafter isopropyl alcohol was 
removed and the loading gel (4 % acrylamide) was poured. Details for acrylamide gel ingredients are 
listed in table 3-10. 
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Table 3-10: Summary of acrylamide gel contents. 
 
Separating gel  Ingredients 
  7.5 %  12.5 % 
Loading gel  
   4 %  
Acrylamide (30 %)  2.4 ml   3.9 ml   0.48 ml 
Separating gel buffer pH 8.8  2.5 ml   2.5 ml      - 
Loading gel buffer pH 6.8    -     -   1.25 ml 
H2O bidest.  7.0 ml   5.5 ml   3.17 ml 
SDS (10 %) 100 µl  100 µl    100 µl 
Ammonium persulfate (10 %)   75 µl    75 µl      38 µl 
TEMED (100 %)  7.5 µl   7.5 µl     3.8 µl 
 
The gel was loaded with equal amounts of protein (6 µg) for each sample. To define the molecular 
weight of the proteins, a Full Range Molecular Weight Marker Rainbow and a Precission Plus Protein 
Kaleidoscope Standard were added on the gel. Proteins were separated using 1 x electrophoresis buffer 
(Laemmli) and 190 V and 400 mA for about 1 h.  
 
3.3.3 Western blot 
The proteins were blotted from the gel onto a nitrocellulose membrane employing a Wet-Blot-System 
in a Mini Trans-Blot® chamber. Transferblotting was carried out at 100 V and 400 mA for 1 h. 
Afterwards the proteins on the membrane were visualized by staining them with 1 x Ponceau S. 
Blocking of non-specific binding was achieved by incubating the membrane in 5 % non-fat dry milk 
in Tris buffered saline (TBS)-Tween 20 or 5 % BSA in TBS-Tween 20 for 30-60 min. BSA blocking 
solution was only used in cases where phospho-extracellular regulated kinase (Erk) 1/2 should be 
detected, for all remaining antibodies non-fat dry milk blocking solution was used. Membranes were 
incubated with the following antibodies over night: monoclonal goat anti-human DCN antibody 
(1:1,000), monoclonal mouse anti-human α-SMA antibody (1:500), polyclonal rabbit anti-human Erk 
1/2 antibody (1:1,000), monoclonal mouse anti-human phospho-Erk1/2 antibody (1:1,000), rabbit anti-
phospho-PDGFR-β  antibody (1:100), anti-phospho-EGFR antibody (1:250), monoclonal rabbit anti-
human EGFR antibody (1:100) and polyclonal rabbit anti-human PDGFR-β antibody (1:200).  
Antibody details are summarized in table 10-3 (see APPENDIX 10.3). 
Proteins were detected in a Chemi smart 5000 chemiluminescence instrument using a 
chemiluminiscent reagent. Afterwards a β-actin antibody (1:5,000) was used to allow corrections for 
small differences in loading. Western blot bands were analyzed densitometrically with ImageJ 
Software and the results normalized to the ones obtained for β-actin. 
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3.3.4 Enzyme-linked immunosorbent assay 
DCN was detected in conditioned media (3 days) using a commercial enzyme-linked immunosorbent 
assay (ELISA). Medium supernatants (total 2 ml per 60-mm dish) of the same tryptase/SLIGKV-
treated and untreated control cells, which were used in the Western blot experiments, were examined 
in duplicates. Standards were contained in the ELISA kit. All working steps were performed at room 
temperature. A 96-well microplate was covered with 100 µl Capture Antibody (2.0 µg/ml) per well 
and incubated overnight. The plate was washed three times with buffer  (0.05 % Tween 20 in PBS; pH 
7.2 – 7.4) before blocking for 1 h in 300 µl of reagent diluent (1 % BSA in PBS; pH 7.2 – 7.4). The 
wash steps were repeated. 100 µl of each sample (conditioned media diluted in reagent diluent 
1:1,000) and standards (0 – 1000 ng/ml) were added and the plate was incubated for 2 h. After 
repeating the wash steps, 100 µl Detection Antibody (250 ng/ml) were added to each well and 
incubated for 2 h. The wash steps were repeated, before 100 µl of Streptavidin-horseradish peroxidase 
(HRP; 1:200) were added. The plate was incubated for 20 min avoiding direct light and then washed 
again. 100 µl Substrate Solution (1:1 mixture of Color Reagent A and Color Reagent B) per well were 
added and the plate was incubated for 20 min avoiding direct light. To stop the reaction, 50 µl stop 
solution (1 M sulfuric acid) were added to each well and the optical density was detected immediately 
using a FLUOstar Optima reader (software: Optima version 2.20) at 450 nm and 540 nm wavelength. 
Readings at 540 nm were subtracted from readings at 450 nm to correct for optical imperfections in 
the plate. DCN amounts of each sample were calculated accordingly to the standards and results were 
expressed as secreted DCN per total cellular protein.  
 
3.3.5 Phosphorylation experiments: Proteome Profiler and Western blot 
To obtain a profile of RTKs phosphorylated by DCN, a commercial antibody-based array for 42 
differnet human phospho-RTKs was performed. A total of 106 cells, HTPCs and HTPC-Fs 
respectively, were seeded on a 60-mm plastic culture dish and treated for 5 min with 10 µg/ml DCN, a 
concentration, which induced robust increases in intracellular Ca2+ (described below, see 3.8) PBS was 
added to the culture medium of control cells. Cellular protein was extracted using a Nonident P-40 
(IGEPAL) lysis buffer. Lysates from DCN-treated and untreated cells were added to respectively one 
nitrocellulose membrane on which capture and control antibodies were spotted, and incubated 
overnight at 4 °C on a rocking platform shaker. After three wash steps with TBS containing 0.1  % 
Tween 20, membranes were incubated with an anti-phospho-tyrosine HPR detection antibody for 2 h 
at room temperature on a rocking platform shaker. The wash step was repeated. Chemiluminiscent 
reagent was added and images were captured. Results were evaluated with ImageJ Software. The 
experiment was repeated with cell lysates of two different patients (HTPCs). 
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The ability of DCN to phosphorylate EGFR and PDGFR, was further studied in Western blot 
experiments as described above. For each experiment cells were freshly trypsinized and grown over 
night on a 60-mm. Cells of three men with normal testis and two men with testicular fibrosis were 
treated each with 10 µg/ml BSA, 10 µg/ml DCN, 50 ng/ml EGF or 5 ng/ml PDGF-BB for 10 min. 
Control cells were incubated with PBS added to the culture medium.  Cellular protein was isolated and 
immunoblots with anti-phospho-PDGFR-β and anti-phospho-EGFR antibodies were performed as 
described above. For control purposes, anti-EGFR and anti-PDGFR-β antibodies were used. 
 
 
3.4 Immunohistochemistry  
Testis tissue, stemming from humans, mice, rats, hamster or monkeys, was fixed in Bouin`s fixative, 
embedded in paraffin, and sections of a thickness of 5 µm were produced using a microtome. The 
slices were mounted on glass slides.  
For immunohistochemistry the sections were deparaffinized by putting the sections in xylene and 
isopropyl alcohols (100 %, 90 %, 80 %, 70 %). Afterwards the sections were rehydrated with PBS. 
Subsequently, the sections were pretreated in 10 mM sodium citrate buffer in a microwave oven. 
Slides were allowed to cool and then rinsed with three times with PBS for 5 min before 3 % hydrogen 
peroxide in methanol for 20 min was added to block endogenous peroxidase activity. To reduce 
nonspecific antibody binding the sections were incubated with 5 % normal serum (donkey normal 
serum for DCN antibody and goat normal serum for all the rest of antibodies used) in a humid 
chamber for 30 min at room temperature. Afterwards the sections were incubated with the primary 
antibody against DCN (1:100 or 1:50) or SMA (1:2,000) in a humid chamber over night at 4 °C. The 
same antibodies as for Western blot experiments were used. Antibody details are summarized in table 
10-3 (see APPENDIX 10.3). Incubation with normal non-immune serum instead of the specific 
antibody, or omission of the primary antibody served as controls. After primary antibody incubation, 
the sections were washed three times with PBS for 5 min and a biotinylated secondary anti-goat or 
anti-mouse antibody (1:500) was applied for 1 – 2 h. Thereafter the sections were treated with avidin-
biotin peroxidase complex (ABC-method (148)) solution for 1 h, followed by two wash steps with 
PBS for 5 min. After incubation with Tris-hydrogen chloride buffer for 10 min, the antibody was 
localized by a color reaction with 3, 3`-diaminobenzedine (DAB) and hydrogen peroxide. The DAB 
reaction was stopped by placing the slides in double-distilled water (ddH2O). Sections were 
dehydrated in isopropyl alcohols with ascending concentrations (70 %, 80 %, 90 %, 100 %) and 
xylene and finally coverslipped with entellan.  
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3.5 Immunocytochemistry  
Cells were seeded on glass cover slips that were placed in a 24-well microplate. After wash the cells 
two times with 500 µl PBS, they were fixed with 250 µl paraformaldehyde solution (PFA; 4 % in 0.01 
M PBS; pH 6.8) for 30 min. Fixation was followed by several wash steps (3 x PBS for 5 min, 3 x 
KPBS for 10 min) and cells were incubated in LKPBS for 10 min. Afterwards, cells were incubated in 
the presence of a primary antibody, diluted in LKPBS, over night at 4 °C. Monoclonal mouse 
antibodies against SMA (1:2,000), CD90 (1:100), collagen type I (1:200) and type IV (1:250) were 
employed. For controls, the primary antibody was omitted. Next day, the cells were washed three 
times with KPBS for respectively 5 min and once with LKPBS for 10 min. All following steps were 
performed avoiding direct light. Cells were incubated with a fluorescein isothiocyanate (FITC) labeled 
secondary antibody (1:200 in LKPBS) for 1 h at room temperature and afterwards washed three times 
with KPBS for 10 min. Finally, cells were washed once with ddH2O for 5 min. The cover slips were 
covered with Prolong Antifade Kit and placed on glass slides. Fluorescence was detected with a 
fluorescence microscope using a stimulation wavelength of 488 nm and an emission wavelength of 
530 nm. 
 
 
3.6 Nuclear staining 
To evaluate mitotic figures of cultured HTPC/-Fs, DAPI staining was employed. Cells were seeded on 
glass cover slips in a 24 well plate and different time periods (6 h, 18 h and 24 h) of treatments with 
DCN (10 µg/ml) or PDGF-BB (5 ng/ml) have been studied. Only at 24 h a significant increase of 
proliferative events in stimulated cells over controls could be observed and therefore a treatment time 
of 24 h was used for subsequent studies.  
In detail, after incubation with DCN, imatinib (10 µM), EGF (10, 50, 250 ng/ml) or PDGF-BB for 24 
h, cells were washed two times with PBS and subsequently fixed with PFA (4 % in 0.0.1 M PBS; pH 
6.8) for 30 min. After washing cells again with PBS and ddH2O, the cover slips were covered with 
DAPI reagent and mounted on glass slides. DAPI, when bound to DNA emits at wavelength of about 
460 nm producing blue fluorescence, was detected using a fluorescence microscope and a stimulation 
wavelength of about 360 nm. At 20 x magnification pictures were taken. Nuclei (> 200/ slide) were 
counted and the percentage of metaphase, anaphase and telophase figures was determined. 
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3.7 Measurement of cell viability and apoptosis 
3.7.1 ATP measurements 
Viability of cells was determined by using the CellTiter-Glo® Luminescent Cell Viability Assay which 
is based on quantification of ATP. The amount of measured ATP is directly proportional to the 
number of metabolically active cells present in culture. After cell lysis and ATP release, the luciferase 
reactions starts and mono-oxygenation of luciferin is catalyzed by luciferase in the presence of 
magnesium, ATP and molecular oxygen to oxyluciferin. 
Cells were seeded in quadruplicates on 24-well plates and cultured in DMEM without phenol red and 
FCS for 24 h in the presence or absence of DCN (10 µg/ml), EGF (250 ng/ml), PDGF-BB (5 ng/ml), 
imatinib (10, 20, 50 or 100 µM) or combinations. The assay was performed at room temperature, 
avoiding direct light. The kit reagent was mixed with an equal volume of medium. To induce cell 
lysis, 200 µl of this mixture were added directly to the cells, which were subsequently incubated on an 
orbital shaker for 2 min. To stabilize the luminescent signal, the plate was incubated without shaking 
for 10 min. The luminescence of luciferase reaction was measured in a FLUOstar Optima reader. 
Control cells consistent of incubation with the respective solvent of each substance. To obtain a value 
for background luminescence, control wells containing only medium without cells were included in 
the experiment. The mean of the background values was subtracted from the results. 
 
3.7.2 Caspase assay 
To confirm that DCN does not induce apoptosis in HTPC/-Fs, the activity of cysteine aspartic acid-
specific protease (caspase)-3 and -7 in these cells was measured using the Caspase-Glo® 3/7 Assay. 
Within this assay cell lysis is followed by caspase cleavage of the substrat and generation of a 
luminescent signal, produced by luciferase. The luminescence is proportional to the amount of caspase 
activity.  
Cells were seeded in a 96-well plate and allowed to adhere over night. Afterwards DCN (10 µg/ml) 
was added to the culture medium (DMEM without phenol red and FCS) for 24 h. Untreated control 
cells were included in the experiment, as well. The whole assay was performed at room temperature, 
avoiding direct light. The kit reagent was mixed with an equal amount of culture medium before a 
total of 200 µl was added to the cells. The plate was incubated for 1 h and the luminescence of each 
sample was measured in a FLUOstar Optima reader. Control wells containing only medium without 
cells were included in the experiment to detect background luminescence. The mean of the 
background values was subtracted from the results. 
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3.7.3 CASY - measurements with an automated cell counting device 
Measurements of cells in an automated cell counting device (CASY) were performed to further 
examine the effect of DCN, growth factors (PDGF-BB, PDGF-AA, EGF) or imatinib, on cell 
proliferation or cell diameter. CASY technology assesses cell viability based on the integrity of the 
plasma membrane. Cells are exposed to a low voltage field and the electric current cannot go through 
the intact plasma membrane.  
An equal number of cells was seeded on each 60-mm dish used. Cells were treated either with DCN 
(10 µg/ml), PDGF-BB (5 ng/ml), PDGF-AA (5 ng/ml), EGF (250 ng/ml) or imatinib (10 µM) for four 
days. To one of the treatments groups, DCN was added in combination with EGF/PDGF-BB. Control 
cells, treated with solvents of each substance, were included in each experiment. After the treatment, 
cells were trypsinized and resolved in 1 ml DMEM without FCS and a 1:100 dilution of the cell 
suspension in 10 ml CASYton was used in CASY measurements. 
 
 
3.8 Measurements of intracellular Ca2+ levels 
Cells were grown on a glass cover slip in DMEM supplemented with 10 % FCS for 24 h and 
subsequently loaded with 5 µM fluo-4 acetoxy-methylester (fluo-4AM) for 30 min at 37 °C and 5 % 
CO2. After washing the cells with FCS-free DMEM, the cover slip was transferred into a recording 
chamber mounted on a TCS SP2 confocal microscope.  Fluorescence was monitored at 500-540 nm 
(excitation wavelength: 488 nm) every 2 sec and the intensity was quantified over single cells. To 
assess whether HTPC/-Fs may possess functional PAR-2, changes of intracellular Ca2+ levels were 
recorded on-line during application of 100 ng/ml tryptase or 10 µM agonist peptide SLIGKV like it 
has been described (55, 132). To assess whether HTPCs and HTPC-Fs respond in a similar manner to 
tryptase or SLIGKV the number of responding cells was counted for each experiment and the 
percentage of HTPCs and HTPC-Fs (n = 3/group) responding to 100 ng/ml tryptase and 10 µM 
SLIGKV was determined. 
In initial studies, actions of 10 µg/ml bovine articular cartilage DCN and human recombinant DCN on 
Ca2+ signaling were compared. As no difference in the ability of the DCN preparation to mobilize 
intracellular Ca2+ was observed, bovine DCN was generally used for subsequent studies, but for each 
experiment human recombinant DCN was tested, as well. Furthermore, experiments testing different 
concentrations of EGF (50 ng/ml, 250 ng/ml and 1 µg/ml) and PDGF-BB (5 ng/ml and 10 ng/ml) were 
conducted. 50 ng/ml EGF and 5 ng/ml PDGF-BB proved to be effective stimulators of Ca2+ release, 
therefore these concentrations were used for subsequent experiments. In additional studies, HTPCs as 
well as HTPC-Fs were pretreated with 10 µg/ml DCN for 24 h before measuring Ca2+ levels upon 
EGF, PDGF or DCN stimulation. Additionally, Ca2+ signals were recorded after addition of 100 µM 
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histamine which served as a positive control (55). Measurements with 10 µl/ml BSA (pH = 7.8) were 
performed to exclude non-specific protein effects. 
 
 
3.9 Laser capture microdissection  
Human biopsies embedded in paraffin wax were cut in 5 µm-thin sections and mounted onto a       
1.35 µm-thin polyethylene naphthalene membrane pasted to a glass object slide. The sections were 
deparaffinized, lightly stained with haemalaune/eosin and subjected to laser capture microdissection. 
The peritubular compartment was cut out using the high photonic energy of a nitrogen laser. To isolate 
the microdissected area from the surrounding tissue, the laser was focused below the specific region 
and with a single laser shot the tissue was catapulted from the slide into the cap of a 0.5 ml microfuge 
tube. 50 µl of RNA stabilization reagent were added to each sample, before they were shortly 
centrifuged and frozen at -80 °C until RNA extraction was performed. RNA was extracted using a 
QIAGEN RNeasy FFPE kit. Reverse transcriptase PCR using oligo-dT primers was performed. RT-
PCRs, using nested (for amplifying EGFR and PDGFR-α) or semi-nested (for amplifying PDGFR-β) 
primers, were performed as described above. In order to ensure that the sections contained suitable 
RNA for this procedure, a whole deparaffinized consecutive section was also scraped from the slide 
and processed as described. For informations on primers and annealing temperatures, please see table 
10-1 (APPENDIX 10.1). 
 
 
3.10 Data analysis 
Results of PCR, Western blot and dot blot experiments were analyzed using the public domain image 
processing program, ImageJ (version 1.40g; NIH, MD, USA). 
Results obtained were analyzed using PRISM 4.0 (GraphPad Software, Inc., San Diego, CA). Student 
t-tests or one-way ANOVAs were performed, as indicated. Differences between the groups were 
evaluated with the appropriate post hoc tests (e.g. Newman-Keuls Multiple Comparison). All data are 
expressed as mean ± SEM. 
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4.1 DCN expression in the mammalian testis 
4.1.1 Testicular DCN expression in the human, non-human primate and the mouse 
Initially, DCN mRNA expression was examined in the testes of three different mammalian species, 
namely human, rhesus monkey and mouse. RT-PCR experiments, using mouse-specific primer pairs 
for mouse samples, human DCN primer pairs for human and rhesus monkey samples (in case of 
rhesus monkey human nested DCN primers were used additionally) revealed DCN mRNA in the 
testes of all examined species (Figure 4-1). All amplified PCR products were verified after 
sequencing. 
 
 
Figure 4-1: Testicular DCN mRNA expression in adult human, monkey 
and mouse. 
Amplified RT-PCR products were visualized using an ethidium bromide 
stained gel. DCN mRNA is expressed in commercial testicular human cDNA, 
in whole testis tissue samples from monkeys and mice (human DCN: 221 bp; 
human nested DCN: 122 bp; mouse DCN: 181 bp; -: no input cDNA). 
 
 
Testicular DCN was detected by immunohistochemistry. In the testes of adult humans and rhesus 
monkeys (Figure 4-2 A, C; n = 3 humans; n = 3 monkeys) DCN staining in the ECM of the interstitial 
and the peritubular compartment, as well as staining of peritubular cells became evident. As the 
cytoplasm of peritubular cells also stained, these cells are likely the producers of DCN. In contrast to 
the strong expression in human and rhesus monkey testis, in testes samples of adult rodents (mouse, 
rat, hamster), no or a very low DCN staining was found (Figure 4-2 D, E, F). Controls in which the 
primary antibody was omitted (Figure 4-2 B) or replaced by non-immune serum, were negative. 
Western blotting confirmed DCN expression in human testicular biopsies of men with normal 
spermatogenesis (data not shown). 
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Figure 4-2: Sites of DCN expression in testes of adult man, 
non-human primate and rodents.  
A, Immunohistochemical DCN staining is located to the 
peritubular wall and interstitial areas in normal human testis. B, 
Control (human biopsy), in which the antiserum was replaced 
by buffer, was immunonegative. C, In the testis of rhesus 
monkey DCN staining is located to peritubular areas. No or 
very low levels of DCN could be detected in the testis of D, 
mouse, E, hamster and F, rat. The length of the scale bars in 
each picture is approximately 100 µm. 
 
 
4.1.2 Testicular DCN expression in human sub-/infertility  
The distribution pattern of immuno-positive DCN in the testes of men with MA (n = 8), GA (n = 3) 
and SCO syndrome (n = 4) patients was similar to that observed in testis of fertile men. However, in 
these cases of impaired spermatogenesis and interstitial and tubular fibrosis, DCN staining of the 
affected peritubular region, both in the cytoplasm of peritubular cells and in the thickened ECM of the 
peritubular wall (Figure 4-3 A-C), was increased when compared to biopsy samples of healthy testis. 
As seen in sections of MA patients (Figure 4-3 A), the accumulation of DCN in the thickened ECM of 
completely fibrotically remodeled tubules strongly contrasted to only weakly stained ECM areas of 
adjacent walls of normal tubules with larger diameter and without fibrotic remodeling. In the 
massively fibrotically altered tubular walls of patients suffering from GA (Figure 4-3 C) DCN staining 
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was abundant, as well. DCN deposits in the thickened layers of the ECM were observed. Samples of 
SCO syndrome patients  (Figure 4-3 B) showed clear DCN staining in the fibrotically thickened ECM 
of the peritubular walls and in cells of the interstitial compartment. The peritubular region in MA, GA 
and SCO syndrome patients was clearly shown by specifically staining of corresponding sections with 
an antibody against SMA (Figure 4-3 D-F). All of the controls, performed with non-immune serum 
(Figure 4-3 I) and omission of primary antibody (Figure 4-3 G, H), showed negative immuno-
histochemical staining.  
 
 
Figure 4-3: DCN in the testis of infertile men.  
DCN deposits are observed in the interstitial region and several, massively remodeled tubules 
(asterisks) in biopsies of A, MA, B, SCO and C, GA patients. D-F, SMA staining to indicate the 
peritubular region in MA, GA and SCO patients. G and H, Controls in which the primary antibody 
was omitted were negative. I, Control staining in which the primary antibody was replaced by non-
immune serum was negative as well. The length of the scale bar in A is approximately 200 µm and 
in B and C 100 µm. 
 
 
4.1.3 DCN expression in the testis of infertile AROM+ mice 
Results of qRT-PCR measurements showed low DCN mRNA levels in the testes of WT mice at the 
age of 5, respectively, 10 months (Figure 4-4 A). Compared to WT, significantly increased DCN 
mRNA expression levels in the testes of 5-month-old transgenic AROM+ mice (P < 0.05;           
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Figure 4-4 A) were observed. While DCN mRNA expression level is not significantly altered in testes 
of aged WT mice, it further increases in AROM+ mouse testes.  
Below the age of 2 – 3 months, AROM+ mice have normal testicular morphology and function, but 
then develop progressive age-dependent testicular fibrosis, inflammatory reactions and disturbed 
spermatogenesis (135). Immunohistochemistry results of AROM+ mouse samples showed that these 
changes were correlated with high levels of testicular DCN (Figure 4-4 D). In 3-month-old AROM+ 
mice DCN staining is likewise low as in testicular samples of adult WT animals (Figure 4-2 D), but it 
can be already detected in the interstitial areas and the peritubular compartments (Figure 4-4 B). At the 
age of 9 – 10 months an enormous DCN expression in the peritubular region and the enlarged 
interstitial areas was apparent in testes of AROM+ animals (Figure 4-4 D). All controls performed 
with non-immune serum or omission of primary antibody showed negative immunohistochemical 
staining (Figure 4-4 C). 
 
 
Figure 4-4: DCN accumulation in the testis of AROM+ mice.  
A, QRT-PCR results of screening of whole testis samples of WT and AROM+ 
mice (5- and 10-month-old). Results (mean + SEM) were normalized to the 
housekeeping gene RPL19 and are given in arbitrary units (a.u.). Statistically 
significant differences (P < 0.05) are indicated by different letters above the 
columns. Numbers within the columns indicate the number of individuals per 
group. B, Immunhistochemical staining for DCN in the testis of an AROM+ 
mouse at 3 months of age is low, but it is already evident in some peritubular and 
in interstitial regions (arrows). The bar represents a length of approximately    
100 µm. C, The control in which the antiserum was replaced by buffer is 
immuno-negative. The length of the bar is approximately 50 µm. D, DCN 
accumulates massively in testicular interstitial cells of a 9-month-old AROM+ 
mouse. The length of the bar is approximately 50 µm.  
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4.1.4 Testicular DCN expression during rhesus monkey development 
Testicular DCN during ontogeny was studied in the non-human primate. In young, prepubertal rhesus 
monkeys, immunohistochemical staining showed strong DCN immunoreactive signals associated with 
connective tissue cells (Figure 4-5 A, B). DCN is massively expressed in the peritubular wall and 
within the interstitial compartment. In contrast, in adult monkeys, in which connective tissue is 
reduced, DCN levels decreased and distinctly marked the peritubular wall and interstitial areas (Figure 
4-5 D-F), comparable to normal human testes (Figure 4-1 A). 
 
 
Figure 4-5: DCN during testicular development in the rhesus monkey 
A, Immunohistochemical staining for DCN in the testis of a prepubertal rhesus monkey (193 days of age). 
DCN is strongly expressed in peritubular and interstitial regions. The length of the bar is approximately    
50 µm. B, Magnified view of the boxed area in A. DCN staining of cells of the peritubular wall (arrows) 
and the interstitial area of a prepubertal monkey testis. The length of the bar is approximately 25 µm. C, 
Control (prepubertal animal) in which the antiserum was replaced by buffer (bar: approximately 50 µm).  
D, Testicular DCN can be detected in a rhesus monkey at the age of 5 years and 343 days. DCN staining is 
seen in peritubular and interstitial regions. The length of the bar is approximately 50 µm. E, In the testis of 
monkey of 27 years and 205 days of age a low DCN expression in the peritubular area can be detected. The 
bar is approximately 50 µm in length. F, Magnified view of the boxed area in E. DCN staining of cells of 
the peritubular wall (arrows) and the interstitial area is low in an adult monkey testis. The length of the bar 
is approximately 25 µm. 
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4.2 Cultured human testicular peritubular cells – a cellular model to study male infertility 
4.2.1 Expression of smooth muscle cell and fibroblast markers 
In the present study cultured human testicular peritubular cells derived from patients with normal 
spermatogenesis (HTPCs) and corresponding cells stemming from sub-/infertile patients (HTPC-Fs), 
were investigated. A couple of experiments have been performed to show that HTPC and HTPC-Fs 
are comparable cellular models, derived from the peritubular region in the testis.  
RT-PCR results revealed that HTPCs, as well as HTPC-Fs, express several markers for fibroblasts 
(collagen type IV and CD90) and smooth muscle cells (SMA, MYH11 and calponin; Figure 4-6 A). 
Cells of three different individuals of each group, HTPC and HTPC-F, were tested in RT-PCR 
experiments. The identities of all amplified PCR products were verified by sequencing. Western blot 
studies with cells of at least eight different patients of each group, HTPC and HTPC-F, confirmed RT-
PCR results for SMA at protein level and furthermore showed that both cell types express similar 
amounts of SMA (Figure 4-6 B).  
 
 
Figure 4-6: HTPCs and HTPC-Fs express several fibroblast 
and smooth muscle cell markers. 
A, RT-PCR results show the expression of collagen type IV and 
CD90 (fibroblast markers) and SMA, MYH11 and calponin 
(smooth muscle cell markers) in HTPC/HTPC-Fs. Representatives 
of results obtained in three different patients/group are shown. 
Cyclophilin amplifications were used to evaluate differences in 
applied cDNA amounts. B, Summary of Western blot results 
(mean + SEM) indicate that HTPCs and HTPC-Fs do not differ in 
SMA expression levels. To account for possible small differences 
in applied protein amounts, SMA levels were normalized to β-
actin levels and given in a.u. The numbers within the columns 
indicate the number of individual patients used for this experiment. 
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Smooth muscle cell and fibroblast characteristics of HTPCs as well as HTPC-Fs were further proven 
in immunocytochemical stainigs. Both cells types were positive for collagen type I and type IV, SMA 
and CD90 (Figure 4-7). Cells stemming from respectively three different men per group were used. 
No differences in expression patterns of these markers in HTPCs and HTPC-Fs have been observed. 
Results obtained for HTPCs have been published previously (55). 
 
 
HTPC   HTPC-F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: Equal expression 
patterns of collagen type I and IV, 
SMA and CD90 in HTPC/-Fs.  
Representative immunocytochemistry 
results of HTPCs (left) and HTPC-Fs 
(right) show expression of collagen 
type I and type IV, SMA and CD90. 
Cells of 3 patients/group (HTPC/-F) 
were stained. Negative controls were 
performed by omitting the primary 
antibody (-). The length of the bar is 
approximately 10 µm. 
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4.2.2 Expression of receptors in HTPCs and HTPC-Fs 
 
HTPCs and HTPC-Fs express functional receptors for immune cell products 
It has been already shown that mRNAs of receptors for tryptase (PAR-2) and TNF-α (TNFR-1/-2) are 
expressed in HTPCs and HTPC-Fs (55, 132, 133). 
To investigate if HTPCs and HTPC-Fs respond in a similar way to PAR-2 activation, measurements of 
transient intracellular Ca2+ release, after addition of human recombinant tryptase (100 ng/ml) or a 
selective PAR-2 agonist peptide SLIGKV (10 µM), were performed. Tryptase and SLIGKV led to 
acute Ca2+ elevations in HTPCs and HTPC-Fs (Figure 4-8 A, B), indicating that functional PAR-2 is 
expressed in either cell type. The number of responding cells was counted for each experiment and the 
percentage of HTPCs and HTPC-Fs (n = 3/group) responding to 100 ng/ml tryptase and 10 µM 
SLIGKV was determined. Results indicate a similar response in both cell types (Figure 4-8 C). As  
100 ng/ml tryptase and 10 µM SLIGKV proved to be effective concentrations to induce Ca2+ signals in 
HTPC/-Fs, these concentrations were used for subsequent studies.  
 
 
Figure 4-8: HTPCs and HTPC-Fs bear a functional receptor for tryptase, PAR-2. 
A, Representative results of measurements of intracellular Ca2+ release after addition of tryptase (100 ng/ml) and 
agonist SLIGKV (10 µM) in single HTPCs and B, HTPC-Fs. The arrowheads indicate the addition of buffer 
(DMEM). C, The percentage of HTPCs and HTPC-Fs (n = 3 patients/group) responding to tryptase/SLIGKV 
with acute Ca2+ signals were not significantly different (mean + SEM).  
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Previous studies indicated that TNFR-1 and -2 are expressed in the human testis and in HTPCs and 
HTPC-Fs (132, 133). In the present study, functionality of these receptors in HTPC-Fs was 
investigated as has been described for HTPCs (133). TNF-α binding to TNFRs activates MAPK 
cascade and leads to phosphorylation of Erk1/2 (149). Western blot experiments with TNF-α             
(5 ng/ml) stimulated HTPC/HTPC-F samples were performed and phosphorylation of Erk1/2 in both 
cell types could be demonstrated after 10 and 20 min, but not after 60 min, of TNF-α stimulation 
(Figure 4-9). These results indicate the presence of functional TNFRs in HTPCs as well as in HTPC-
Fs. Cells isolated of respectively three different patients per group were used for this experiment. 
 
 
 
Figure 4-9: HTPCs and HTPC-Fs possess functional TNFRs. 
Results of Western blot experiments performed at different time points revealed phosphorylation of 
Erk1/2 (Phospho-Erk1/2) after 10 and 20 min, but not after 60 min, of TNF-α treatment (5 ng/ml) of 
HTPCs (left) and HTPC-Fs (right). All results were normalized to levels of total Erk1/2 and are given 
as mean + SEM (a.u.). Numbers within the columns indicate the number of different patients. 
Examples of representative Western blots of HTPCs (left) and HTPC-Fs (right) are shown below. 
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HTPCs and HTPC-Fs express several growth factor receptors 
Several growth factor receptors are known from other cellular systems to be partners of DCN 
signaling (121-124). RT-PCR screening followed by sequencing revealed that cultured HTPCs, as 
well as HTPC-Fs, express a number of those growth factor receptors. The data indicate mRNA 
expression of receptors of the EGFR family, namely EGFR, v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2 (ErbB2), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ErbB3) 
and v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ErbB4), PDGF receptors (PDGFR-α 
and PDGFR-β), IGF-1R, HGFR and VEGR (Figure 4-10). For each PCR samples of three different 
patients per group were used.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10: Growth factor receptor expression 
in HTPC and HTPC-Fs. 
Results of RT-PCR analysis are shown using 
ethidium bromide-stained gels. HTPCs and HTPC-
Fs express receptors of the EGFR family (EGFR, 
ErbB2, ErbB3 and ErbB4), PDGFRs (-α and -β), 
VEGFR, HGFR and IGF-1R. Negative controls 
were performed without cDNA input (- control). 
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In the present study, DCN interferences with the EGF/EGFR and PDGF/PDGFR signaling systems 
were examined. In order to determine whether EGFR and PDGFRs are expressed in the human 
peritubular wall in vivo, this compartment was isolated by laser capture microdissection and 
subsequently subjected to RT-PCR and sequencing. Sections of normal testis and testis of MA patients 
were used. The results revealed EGFR- and PDGFR (-α and -β)-expression in the peritubular wall of 
normal human testis as well as in testis with spermatogenic failure. Evidence for EGFR and PDGFR-α 
and -β mRNA expression was also found in sections of whole testes, which had been scraped from the 
slide and used as a positive control (Figure 4-11). 
 
 
Figure 4-11: Expression of EGFR/PDGFR in the peritubular 
wall of human testis. 
A and B, Micrographs showing a human testicular biopsy of an 
MA patient before and after laser microdissection. Areas of the 
peritubular wall were excised, RNA was extracted and subjected to 
RT-PCR. The length of the scale bars is approximately 50 µm. C, 
Ethidium bromide-stained gel, showing results of a RT-PCR 
experiment (EGFR: 195 bp, PDGFR-α nested: 158 bp, PDGFR-β 
semi-nested: 136 bp). EGFR and PDGFR-α and -β are expressed 
in human peritubular wall (PT). HTPCs and whole testes cDNAs 
were used as positive controls. The negative control was performed 
without cDNA input.  
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4.3 Human testicular peritubular cells express DCN in vitro: Higher basal DCN levels in HTPC-
Fs than in HTPCs  
RT-PCR/sequencing, Western blotting and ELISA measurements revealed that isolated HTPCs and 
HTPC-Fs (n = 3-7 patients/group) produce and secrete DCN (Figure 4-12). However, both cell types 
differ apparently in DCN expression quantity. QRT-PCR showed that within 24 h DCN mRNA 
expression levels are significantly elevated in HTPC-Fs as compared to HTPCs (Figure 4-12 A). All 
results were normalized to the human housekeeping gene RPL19.  
A significant increase in cellular DCN protein in HTPC-Fs as compared to HTPCs could be found by 
Western blotting (P < 0.01). To account for possible small differences in applied protein amounts, 
DCN results were normalized to β-actin levels (Figure 4-12 B). Additionally, ELISA experiments 
revealed that within 24 h, HTPC-Fs released significantly greater quantities of DCN into the culture 
medium than HTPCs. Constitutive secretion occurred and the levels further increased up to 72 h 
(Figure 4-12 C). These data, showing higher expression and secretion of DCN in HTPC-Fs, correlate 
with immunohistochemistry results indicating massive DCN deposits in ECM in the testes of infertile 
men (Figure 4-3 A-C).  
 
 
 
Figure 4-12: HTPCs and HTPC-Fs produce and secrete DCN: Quantitative differences.  
A, QRT-PCR results show a significantly higher DCN mRNA expression in peritubular cells of patients with 
fibrotically altered testes and impaired spermatogenesis than in patients displaying normal spermatogenesis      
(P < 0.01). Results were normalized to the housekeeping gene RPL19. B, Summary of DCN Western blots 
reveal a significant increase in cellular DCN protein in HTPC-Fs as compared to HTPCs (P < 0.01). To account 
for possible small differences in applied protein amounts, DCN levels were normalized to β-actin levels.           
C, Results of ELISA measurements show an increased DCN protein release from HTPC-Fs into the culture 
media over a period of 24 h (P < 0.05). DCN secretion is further increased after 72 h. ELISA results were 
normalized to total cellular protein. Results were expressed as mean + SEM and given in a.u. or pg/mg protein. 
The numbers within columns show the number of different patients. 
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4.4 Regulation of DCN in human testicular peritubular cells 
4.4.1 Testosterone and 17β-estradiol do not influence DCN expression in HTPC and HTPC-Fs 
In order to find how DCN expression is regulated in the peritubular wall of normal and infertile testis, 
HTPCs and HTPC-Fs were treated with testosterone (100 nM) for 24 h and in separate experiments 
with two different concentrations of 17β-estradiol (100 nM and 1 µM) for 6 respectively 24 h. Control 
cells were incubated only with the solvents of stimulants. QRT-PCRs revealed that testosterone, when 
added to the cells for 24 h, is not able to alter DCN mRNA levels in HTPC/-Fs compared to controls 
(Figure 4-13 A). Both concentrations of 17β-estradiol, added for different time periods, do not 
influence DCN mRNA expression either (Figure 4-13 B, C). 
 
 
Figure 4-13: Testosterone and β-estradiol do not alter DCN mRNA expression in HTPC/-Fs. 
QRT-PCR results of screening of respectively cells from three patients with normal spermatogenesis and three 
patients with fibrotic altered testes and impaired spermatogenesis show that neither A, testosterone (100 nM) 
after 24 h stimulation nor β-estradiol in different concentrations (100 nM and 1 µM) for B, 6 respectively C, 24 
h can change DCN mRNA expression. All results (mean + SEM) were normalized to the housekeeping gene 
RPL19 and are given in arbitrary units (a.u.). The numbers within the columns indicate the number of patients. 
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4.4.2 Forskolin and prostaglandin 15dPGJ2 do not affect DCN expression 
HTPCs and HTPC-Fs were treated with forskolin (50 nM) for 4 h and in a separate experiment with  
15dPGJ2 (10 µM) for 7 days. Control cells were incubated only with the solvents of stimulants. QRT-
PCRs revealed that both treatments do not alter DCN mRNA levels in HTPC/-Fs compared to controls 
(Figure 4-14). 
 
 
Figure 4-14: Forskolin and 15dPGJ2 do not affect DCN mRNA expression in HTPC/-Fs. 
A, Forskolin (50 nM) after 4 h stimulation and B, 15dPGJ2 (10 µM) after 7 days do not change 
DCN mRNA expression. All results (mean + SEM) were normalized to the housekeeping gene 
RPL19 and are given in arbitrary units (a.u.). The numbers within the columns indicate the number 
of different patients. 
 
 
 
4.4.3 Tryptase stimulates DCN production and secretion via PAR-2 after 72 h in HTPC-Fs, but 
not in HTPCs 
The number of tryptase producing mast cells is increased in the testes of sub-/infertile men (54, 150). 
As mentioned above HTPCs, as well as HTPC-Fs, express functional receptors for tryptase, PAR-2. 
QRT-PCR analysis showed that tryptase (100 ng/ml) does not influence DCN mRNA regulation in 
HTPC/-Fs after a stimulation period of 24 h (Figure 4-15 A). ELISA experiments confirmed these 
results at protein level (Figure 4-15 B). 
 
 
48                         4. RESULTS 
 
 
Figure 4-15: DCN expression in HTPC/-Fs is not altered by tryptase after 24 h. 
A, QRT-PCR data show that tryptase treatment for 24 h (100 ng/ml) does not alter DCN mRNA 
expression levels in HTPC and HTPC-Fs. Results (a.u.) were normalized to the housekeeping gene 
RPL19. B, Results of ELISA experiments show that neither tryptase, nor SLIGKV (10 µM) after 24 h, 
alter DCN protein secretion amounts of HTPC/-Fs. Levels of secreted DCN were normalized to the 
total amount of protein of each sample. Numbers within columns show the number of patients. 
 
 
When cells were stimulated for 72 h with tryptase (100 ng/ml) or SLIGKV (10 µM), a regulation of 
DCN expression in HTPC-Fs, but not in HTPC, could be observed. Tryptase and SLIGKV increased 
not only DCN mRNA expression, but also cellular and secreted protein levels. Compared to the 
corresponding control cells, DCN mRNA and protein levels in stimulated HTPC-Fs, but not HTPCs, 
are significant higher (Figure 4-16). 
 
 
 
Figure 4-16: Tryptase treatment for 72 h stimulates DCN production and secretion in HTPC-Fs. 
A, QRT-PCR results show DCN mRNA expression levels in HTPCs and HTPC-Fs, after 72 h exposed to       
100 ng/ml tryptase or 10 µM SLIGKV. DCN mRNA levels in stimulated HTPC-Fs are significantly increased 
compared to controls (P < 0.05; mean + SEM). DCN mRNA levels in HTPCs are not changed upon stimulation. 
Results (a.u.)were normalized to the housekeeping gene RPL19. B, The summary of Western blot data reveals 
that DCN protein levels in HTPC-Fs are significantly increased by tryptase (100 ng/ml)/SLIGKV (10 µM) after 
72 h (P < 0.05), while they are not altered in HTPCs. Results (a.u.) were normalized to β-actin and given as 
mean + SEM. C, Results of ELISA measurements show a significant increase in secreted DCN amounts in 
tryptase/SLIGKV-treated HTPC-F samples compared to HTPCs and control cells (n = 4/group). Values were 
normalized to total protein amounts. Because of high varation among results of different patients, results were 
normalized to their controls. Numbers within the columns indicate the number of different cell donators.  
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4.4.4 TNF-α  stimulates DCN production and secretion via TNFRs after 72 h in HTPC-Fs, but 
not in HTPCs 
Testicular mast cells and macrophages produce and secrete the cytokine TNF-α (54, 58, 133, 150). 
Recent studies showed, that HTPCs and HTPC-Fs possess TNFR-1 and TNFR-2 (132, 133). 
Functionality of these receptors was proven by detecting phosphorylation of Erk1/2 in HTPC/-Fs after 
10 or 20 min TNF-α (5 ng/ml) treatment (Figure 4-9). DCN expression in HTPC/-Fs was investigated 
after 24 h respectively 72 h treatment with TNF-α (5 ng/ml). No significant changes in DCN mRNA 
expression in HTPC/-Fs after 24 h TNF-α stimulation could be detected (data not shown). However, 
after 72 h HTPC-Fs responded to TNF-α by increasing DCN production (Figure 4-17). DCN mRNA 
levels in HTPC-Fs are significantly elevated upon TNF-α stimulation compared to untreated control 
cells (Figure 4-17 A). No DCN regulation by TNF-α could be observed in cells of fertile patients. The 
qRT-PCR results could be confirmed at protein level by Western blot and ELISA experiments. Thus, 
cellular and secreted DCN amounts of HTPC-Fs are increased by TNF-α after 72 h (Figure 4-17 B, 
C).  
 
 
Figure 4-17: The cytokine TNF-α  stimulates DCN production and secretion in HTPC-Fs. 
A, Results of qRT-PCR: DCN mRNA expression in TNF-α (5 ng/ml) stimulated HTPC-Fs, but not HTPCs, 
is significant higher than in untreated control cells (P < 0.05; mean + SEM). Results (a.u.) were normalized 
to the housekeeping gene RPL19. Numbers within columns show the number of patients. B, Western blot 
results: TNF-α significantly increases DCN protein levels in HTPC-Fs after 72 h (P < 0.05). All results were 
normalized to β-actin protein levels and given in a.u. Results of TNF-α stimulated cells were normalized to 
values of untreated control cells, because of high variation between different patients. Data shown are mean + 
SEM of blots performed with 3 – 5 patients/group. C, ELISA results: Compared to HTPCs and control cells, 
a significant increase in secreted DCN became evident in HTPC-F samples after 72 h TNF-α treatment (P < 
0.05; n = 4/group). All values were normalized to total protein amounts and given in a.u. Results of TNF-α 
stimulated cells were normalized to values of untreated control cells, because of high variation between 
different patients. Data of cells of four patients/group are shown. 
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4.5 Mouse fibroblasts 
4.5.1 TNF-α  increases DCN expression in NIH/3T3 cells 
NIH/3T3 cells, standard mouse fibroblasts were used for initial mouse studies by treating them with 
mouse TNF-α for 24 h and 72 h. QRT-PCRs revealed that DCN mRNA is expressed in NIH/3T3 cells 
and that levels of DCN mRNA are increased by TNF-α treatment for both time periods (Figure 4-18 
A). DCN protein could hardly be detected in NIH/3T3 cells, but when cells were grown in the 
presence of TNF-α for 24 h or 72 h, DCN protein levels were increased (Figure 4-18 B). 
 
 
Figure 4-18: TNF-α  stimulates DCN expression in NIH/3T3 cells. 
A, Results of qRT-PCR indicate an increased DCN mRNA expression after 
treatment with TNF-α (5 ng/ml) for 24 h respectively 72 h. Results were normalized 
to the housekeeping gene RPL19 and are given in a.u. B, Results of Western blotting 
reveal that TNF-α increases DCN protein levels after 24 h/72 h. Results were 
normalized to β-actin protein levels and given in a.u. 
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4.5.2 Mouse testis cell culture 
Explants of mouse testicular tissue of WT and AROM+ were cultured to gain mouse testicular 
peritubular cells. After approximately five days elongated cells extended from the explants (Figure 4-
19 A) which were stained positive with SMA (data not shown). As cell growth was observed only in 
few explant pieces and cells grow slowly, mouse testicular fibroblasts of the interstitial compartment 
were isolated using collagenase. Growing cells showed a morphology that was characterized by 
mainly elongated cells with fibroblast appearance (Figure 4-19 B). As cells have to be used freshly for 
each experiment, because subcultivation was not possible with the methods used, it was not possible to 
gain sufficient cell yields for further experiments within the present study.  
 
 
Figure 4-19: Cultures of mouse testicular cells. 
A, Small pieces of testicular biopsies were seeded onto culture dishes and 
after five days, cells start growing out of the explants. B, Cells of mouse 
testis isolated using collagenase display an elongated phenotype. The length 
of the bar is approximately 20 µm. 
 
 
 
4.6 DCN effects on HTPCs and HTPC-Fs 
4.6.1 DCN acutely increases intracellular Ca2+ levels in HTPC/-Fs  
DCN is known to be a potential signaling molecule that interacts with several growth factor systems in 
various tissues. The present study indicated that a number of growth factor receptors are expressed by 
peritubular cells of the human testis (Figure 4-10). When HTPCs or HTPC-Fs were incubated with 
DCN (10 µg/ml), cells generate an immediate and reversible increase in intracellular Ca2+ (Figure 4-
20). Apparently, DCN can act as a ligand to some receptor linked to signal transduction events 
involving Ca2+ release in HTPC/-Fs. Since the existence of a special DCN receptor is not known, these 
findings suggest DCN interaction with one or more growth factor receptors in HTPC/-Fs. Cells of at 
least three different patients per group, HTPC and HTPC-F, were tested and approximately                
80 – 100 % of the cells measured respond to DCN stimulation with transient elevations of Ca2+. To 
exclude, that Ca2+ signals are only a non-specific protein effect, experiments with BSA (10 µg/ml) 
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were conducted as well. When BSA was added, intracellular Ca2+ levels in HTPC/-Fs were not altered 
(Figure 4-20 C). 
 
 
 
Figure 4-20: HTPC/HTPC-Fs respond to DCN with transient 
intracellular Ca2+ signals. 
A, Microphotograph of HTPCs prior to (-; DMEM) and immediately after 
DCN addition (+; 10 µg/ml). B, Representative results of measurements of 
intracellular Ca2+ levels in a single HTPC (left) and HTPC-F (right): DCN 
(10 µg/ml) leads to acute and repeatable increases in intracellular Ca2+ in 
HTPC/-Fs. Arrows indicate the addition of DCN and arrowheads indicate 
the addition of buffer (DMEM). C, BSA addition (arrows) did not induce 
increased intracellular Ca2+ levels neither in HTPC (left), nor HTPC-Fs 
(right). Arrowheads indicate the addition of DMEM. 
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Furthermore, Ca2+-measurement experiments testing different concentrations of EGF (50 ng/ml,      
250 ng/ml and 1 µg/ml) or PDGF-BB (5 ng/ml and 10 ng/ml) showed that these growth factors can 
increase intracellular Ca2+ in HTPCs and HTPC-Fs in a similar manner as DCN (Figure 4-21). 
Concentrations of 50 ng/ml EGF and of 5 ng/ml PDGF-BB were already sufficient to induce transient 
and reversible calcium signals in the cells, thus proving the functionality of EGFRs and PDGFRs in 
cultured HTPC/-Fs. When cells were pre-treated with 10 µg/ml DCN for 24 h, intracellular Ca2+ levels 
did not change when challenged with EGF or PDGF-BB, but cells still responded to a challenge by 
histamine (data not shown). 
 
 
Figure 4-21: EGF and PDGF-BB induce intracellular Ca2+ signals in HTPC/-Fs. 
Representative results of measurements of changes of intracellular Ca2+ levels in a 
single HTPC (left) and HTPC-F (right) show that EGF (50 ng/ml) and PDGF-BB (5 
ng/ml) lead to acute increases in intracellular Ca2+ in HTPC/-Fs. Arrowheads 
indicate the addition of DMEM. 
 
 
4.6.2 Acute actions of DCN leads to phosphorylation of growth factor receptors in HTPC and 
HTPC-Fs 
To examine whether exogenously added DCN may be able to activate RTKs expressed by HTPC/-Fs 
(Figure 4-10) a phosphorylation assay (Proteome Profiler) to determine the relative level of tyrosine 
phosphorylation of human RTKs was performed. Results of this dot blot screening indicated a 
phosphorylation of several RTKs by DCN (10 µg/ml), added to HTPCs for 5 min. Phosphorylation of 
the EGFR family (EGFR, ErbB2, ErbB3 and ErbB4) and HGFR, but not in cases of VEGFR or IGF-
1R when evaluated in comparison to control cells only treated with PBS, was found (Figure 4-22). 
Differences between results for phosphorylated and non-phosphorylated PDGFR-α/β were small and 
therefore phosphorylation of this growth factor receptor was examined in further experiments using 
Western blotting. Protein array results of all 42 different human RTKs are listened in table 10-11 (see 
APPENDIX 10.11). 
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Figure 4-22: Evidence for DCN acting as a ligand for growth factor receptors in 
HTPCs. 
Results of protein array experiment indicate that DCN (10 µg/ml) causes phosphorylation 
of the EGFR family (EGFR, ErbB2, ErbB3 and ErbB4) and HGFR in HTPCs within        
5 min. A potential, but very low, phosphorylation was found in case of PDGFR-α/β. 
VEGFR and IGF-1R were not phosphorylated by DCN. Data for control cells (white 
columns) and treated cells (dark columns) are given. The values stem from densitometric 
evaluation of two experiments. Results (mean + SEM) shown were normalized to control 
values and expressed as a.u.  
 
 
Since EGF and PDGF-BB were found to induce mitosis and proliferation in HTPCs, as well as in 
HTPC-Fs (see below points 4.6.4 and 4.6.5), possible DCN interactions with EGFR and PDGFR were 
examined further. Subsequent Western blot experiments, using anti-phospho-EGFR and anti-phospho-
PDGFR-β antibodies, revealed that DCN (10 µg/ml) added to HTPCs or HTPC-Fs for 10 min, 
phosphorylates EGFR, but not PDGFR-β (Figure 4-23). As expected, phosphorylation of EGFR and 
PDGFR-β occurred in response to 50 ng/ml EGF or 5 ng/ml PDGF-BB added respectively for 10 min 
to the cells. The experiment was repeated with cells of three men with functional spermatogenesis and 
from two patients with impaired spermatogenesis and testicular fibrosis. Importantly, the addition of 
BSA (10 µg/ml) did not cause signals and therefore a non-specific protein effect can be excluded 
(Figure 4-23). 
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Figure 4-23: DCN phosphorylates EGFR, but not PDGFR-β , in HTPC and 
HTPC-Fs. 
Representative Western blots showing that DCN (10 µg/ml) causes phosphorylation 
of EGFR within 10 min, while PDGFR-β is not phosphorylated. Negative control (-; 
addition of PBS) and BSA (10 µg/ml) treated samples are not phosphorylated as 
well. Control Western blots using non-phosphorylated EGFR and PDGFR-β antisera 
are shown below. 
 
 
4.6.3 Chronic actions of DCN on viability of HTPC and HTPC-Fs. 
To investigate actions of DCN when added exogenously to HTPCs and HTPC-Fs for longer time 
periods (24 h), experiments to assess cell apoptosis and viability were performed. Caspase assays, 
performed 24 h after cell stimulation with DCN (10 µg/ml), revealed that DCN does not induce 
apoptosis in both cell types (Figure 4-24). 
 
 
Figure 4-24: Effect of exogenous DCN on apoptosis in HTPCs and 
HTPC-Fs. 
Results of measurements of caspase 3/7 levels in testicular peritubular 
cells of one patient displaying normal spermatogenesis (left) and cells 
of one patient with impaired spermatogenesis and testicular fibrosis 
(right) show that DCN (10 µg/ml) does not induce apoptosis in both 
cell types. Results are given in relative luminescence units (RLU).  
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Caspase assay results could be confirmed in experiments measuring ATP levels in HTPCs and HTPC-
Fs after different concentrations of DCN (5, 10 and 50 µg/ml) were added for 24 h. ATP assay results 
show that DCN does not alter cellular viability of both cells types (Figure 4-25).  
 
 
Figure 4-25: Effects of different concentrations of DCN on viability of 
HTPC/-Fs. 
Measurements of ATP levels in HTPCs (left) and HTPC-Fs (right) revealed that 
different DCN concentrations (5, 10 and 50 µg/ml) for 24 h did not cause any 
significant alterations in cellular viability. Results (mean + SEM) were 
normalized to untreated controls. The numbers of patients are shown inside the 
columns. Results are given in relative luminescence units (RLU). 
 
 
 
4.6.4 Chronic actions of DCN include inhibition of EGF- or PDGF-mediated viability and 
proliferation in HTPCs and HTPC-Fs 
The roles of EGF and PDGF-BB signaling in human peritubular cells was investigated by measuring 
cellular ATP levels. Results revealed that EGF (250 ng/ml)  and PDGF (5 ng/ml) increased viability of 
HTPCs and HTPC-Fs after 24 h. Interestingly, these growth factor actions were blocked in the 
presence of DCN (10 µg/ml). The data imply that DCN, if present for longer periods, can inhibit 
growth factor signaling (Figure 4-26). Viability experiments were performed with cells of five 
individual men with normal testis and five patients with testicular fibrosis and impaired 
spermatogenesis.  
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Figure 4-26: DCN blocks actions of EGF and PDGF on viability of 
HTPC/-Fs. 
Results of ATP measurements show that EGF (250 ng/ml; top) and PDGF-
BB (5 ng/ml; bottom) are effective stimulators of cellular ATP in HTPCs 
(left) and HTPC-Fs (right) after 24 h. Actions that were significantly blocked 
in the presence of 10 µg/ml DCN (P < 0.05). All results are mean + SEM and 
are expressed in RLU. Results were normalized to values of untreated control 
cells. Numbers of cells from different patients are indicated within the 
columns. Different letters over columns indicate statistically significant 
differences at P < 0.05 between the groups. 
 
 
The role of EGF/EGFR and PDGF/PDGFR and the influence of DCN on these signaling systems in 
HTPC/HTPC-Fs were further examined performing DAPI staining experiments. Evaluating of mitotic 
events revealed that EGF (50 ng/ml) and PDGF-BB (5 ng/ml) significantly stimulate mitosis in 
HTPCs and HTPC-Fs, an effect only observed after 24 h, but not at earlier time points, i.e. 6 h or 18 h 
after treatment (data not shown). DCN (10 µg/ml) did not affect mitosis at any of these time points    
(6 h, 18 h, 24 h), but when it was added in combination with EGF or PDGF-BB to the cells, it 
significantly blocked the mitosis-stimulating actions of both growth factors (Figure 4-27).  
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Figure 4-27: Mitosis induced by EGF and PDGF in HTPC/-Fs is blocked by 
DCN. 
Microphotographs (top) of DAPI stainined nuclei in HTPCs (left) and HTPC-Fs 
(right) represent nuclei in different mitotic states. The length of the scale bar is 
approximately 10 µm. Higher magnification of the boxed area in the left panel 
shows a metaphase nucleus. In HTPC-Fs an anaphase (boxed area in higher 
magnification) and a telophase (arrow) are shown.  
Results of evaluation of mitotic figures (bottom) after 24 h of exposure to EGF  
(50 ng/ml), PDGF-BB (5 ng/ml) and DCN (10 µg/ml) revealed that DCN can 
significantly block EGF/PDGF actions (P < 0.05). The letters above the columns 
indicate statistical differences. Results (mean + SEM) are expressed in percentage. 
The numbers in the columns give numbers of different patients. 
 
 
The ability of PDGF-AA and PDGF-BB to stimulate cellular proliferation was demonstrated in CASY 
experiments. Results of automated cell counts indicated that PDGF-BB (5 ng/ml) added to the culture 
medium for 4 days can significantly increase proliferation of HTPC/-Fs, an action which was blocked 
in the presence of DCN (10 µg/ml; Figure 4-28 A). Similar results were observed in experiments with 
PDGF-AA in combination with DCN and were only performed with cells of one patient displaying 
normal spermatogenesis (data not shown). 
Although expected, PDGF-AA (data not shown) and PDGF-BB did not alter cell sizes of HTPCs or 
HTPC-Fs within 4 days (Figure 4-28 B) as known from studies in rodents (151). Hence actions of 
DCN could not be tested on this aspect. 
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Figure 4-28: DCN blocks proliferation induced by PDGF in HTPC and HTPC-Fs. 
A, Results of automated cell counting after 4 days of exposure to PDGF-BB (5 ng/ml) 
and/or DCN (10 µg/ml). A significant increase in cell number was confirmed in cells 
treated with PDGF-BB (P < 0.05). While DCN alone has no effect, in combination with 
PDGF it significantly blocked the proliferative effect of PDGF in HTPCs and HTPC-Fs 
(P < 0.05). Cells of three different patients/group were used as indicated within the 
columns. Different letters above the columns indicate statistically significant 
differences. B, Measuring of cellular diameter upon stimulation with PDGF-BB           
(5 ng/ml) for 4 days revealed no hypertrophy of HTPCs and HTPC-Fs. Results (mean + 
SEM) of three individuals/group are shown. 
 
 
 
4.6.5 DCN blocks PDGF-BB mediated SMA expression in HTPC/HTPC-Fs 
Semi-quantitative RT-PCR experiments indicated increased mRNA levels of SMA in PDGF-BB 
treated HTPCs and HTPC-Fs after 4 days, indicating differentiation promoting actions of PDGF-BB. 
DCN (10 µg/ml) was able to inhibit this PDGF-BB action on SMA mRNA expression in both cell 
types (Figure 4-29). 
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Figure 4-29: Activation of PDGFR increases SMA expression in HTPC/-Fs,  
an action blocked by DCN. 
Summary of results of semi-quantitative RT-PCR experiments evaluating SMA, 
using cells of three different patients/group (number inside columns). Cells were 
exposed to DCN (10 µg/ml and/or PDGF-BB (5 ng/ml) for 4 days. Densitometric 
evaluation of the bands revealed a significant increase of SMA mRNA levels, 
which was blocked by DCN (P < 0.05). In HTPC-Fs PDGF showed the same 
tendencies, but changes are not significant. Levels of cyclophilin were used to 
normalize the results which represent a.u. 
 
 
4.7 Imatinib – a further inhibitor of PDGF actions in HTPCs 
4.7.1 Imatinib decreases viability in HTPCs in a dose-dependent manner 
Effects of increasing imatinib concentrations on viability of human peritubular cells in vitro were 
investigated by challenging HTPCs with 10, 20, 50 or 100 µM for 24h. Viability of cells, judged by 
ATP measurements, was unaffected by concentrations ≤ 10 µM, but was reduced in a dose-dependent 
manner by higher concentrations (Figure 4-30). Therefore an imatinib concentration of 10 µM was 
used for further analysis.  
 
 
 
 
 
Figure 4-30: Effect of imatinib on 
viability of HTPCs. 
Treatment of HTPCs with imatinib for 
24 h resulted in significantly decreased 
ATP levels in a dose-dependent manner 
(mean + SEM). Results are expressed in 
RLU. Different letters over columns 
indicate statistically significant 
differences at levels of P < 0.05. 
Numbers within the columns represent 
the number of patients. 
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4.7.2 Imatinib inhibits PDGF-BB induced proliferation of HTPCs 
Exposure of HTPCs to 10 µM imatinib had no effect on their viability and proliferation, as shown by 
CASY experiments after 4 days and ATP/DAPI experiments after 24 h (Figure 4-31). However, when 
HTPCs were stimulated with the mitogen PDGF-BB (5 ng/ml), a significant increase in viability and 
cell proliferation was detected compared to untreated control cells as mentioned before. PDGF-
induced effects in HTPCs were blocked in the presence of 10 µM imatinib after 24 h respectively 4 
days (Figure 4-31). 
 
 
Figure 4-31: Effect of imatinib on PDGF-BB induced proliferation of HTPCs. 
A, Results of ATP measurements after 24 h show that imatinib (10 µM) can significantly block PDGF-BB        
(5 ng/ml) induced increased viability of HTPCs (P < 0.05). B, Total cell counts: 5 ng/ml PDGF-BB stimulation 
of HTPCs for 4 days resulted in significant increase of proliferation (P  < 0.05). C, DAPI results: Proportion of 
proliferating cells showing a mitotic figure (%). Imatinib blocks mitogenic actions of PDGF-BB. All results are 
mean + SEM. Different letters indicate significant differences. Numbers in columns indicate the number of 
patients used for cell harvesting. 
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5. DISCUSSION 
5.1 Decorin expression in the testis in health and disease 
In general, reports about proteoglycans in the human testis are rare. Years ago, Ungefroren et al. 
(1995) (89) identified two leucine-rich proteoglycans, biglycan and DCN, in the testis of healthy men. 
DCN was characterized as a product of barely explored, smooth muscle-like cells of the walls of the 
seminiferous tubules and of fibroblasts in the interstitial compartment. Testes of infertile men were not 
examined at that time. In the present study, cellular sites of DCN expression in the adult human testis 
could be confirmed in immunohistochemical studies using biopsies from normal and infertile men 
suffering from MA, GA and SCO syndrome. In addition, a striking accumulation of DCN in the ECM 
of the fibrotically remodeled tubular walls in the testes of men suffering from in- or subfertility was 
found. Since DCN is closely associated with collagens, it s not surprisingly, that it is increased under 
fibrotic conditions where connective tissue is increased. 
As immunohistochemistry indicated, peritubular cells surrounding the seminiferous tubules are the 
source of DCN at this peritubular sites. In infertile men an increased production by these cells, 
possibly along with a reduced ability to degrade DCN, must therefore be responsible for the observed 
deposits in the peritubular compartment. Using a cellular model, namely cultured human testicular 
peritubular cells (HTPCs), it could be shown that peritubular cells synthesize DCN. That indeed 
peritubular cells from infertile men have a greater ability to produce and secrete DCN in a constitutive 
manner, was proven when mRNA and protein levels of HTPCs were compared to those of cells 
derived from infertile men with fibrotically altered testis (HTPC-Fs). This observation leads to the 
assumption that these primary cells mirror the in vivo situation. 
Proteoglycans represent a main component of the ECM. Their ability to interact with several other 
ECM molecules suggest a central role in the assembly and tissue remodeling of the ECM, occurring 
i.e. under fibrotic conditions. The finding of increased testicular DCN during fibrotic conditions is in 
accordance with studies of several human fibrotic diseases of tissues such as kidney (50), lung (152), 
and muscles (153). For instance, in the rat liver, an upregulation of DCN goes in parallel with the first 
signs of fibrotic changes (154), suggesting an important role of the proteoglycan in the early events of 
this pathological process. In patients suffering from chronic pancreatitis, DCN overexpression in the 
growing ECM is associated with desmoplasia and stimulates the expression of mononuclear cell 
recruiting chemokine MCP-1. Other inflammatory cytokines, such as IL-1β and TNF-α, were not 
affected by DCN (155). In fibrotic human testis a similar DCN action might be responsible for fibrotic 
remodeling of the seminiferous tubules walls, a process that remains to be studied in future 
experiments. However, some studies describe DCN as an antifibrotic agent (156, 157). The reduction 
of muscle fibrosis after injury has been shown. Possible antifibrotic functions of DCN in the human 
testis were not studied within the present investigations and remain to be examined. 
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Within the present study, DCN expression in mouse testes was investigated. It was known that in 
normal mice, testicular DCN is undetectable throughout postnatal development and may not be of 
importance in the adult mouse (158, 159). These results are in line with immunohistochemical 
experiments in the present study, which show that it is barely detectable in gonads of young (3 - 5 
moths of age) and old adult (9 - 10 months of age) males. By means of qRT-PCRs, DCN mRNA was 
however detected in mouse testes of both age groups. Thus, DCN in mouse testis may be only present 
at mRNA level or may be only marginally expressed at protein level. Indeed, connective tissue is not 
abundant in mouse testes and therefore DCN is barely present. Another possibility might be, that anti-
human DCN antibody might not work well in mouse. However, in the testis of adult transgenic 
AROM+ mice, which represent a recently found model for male infertility with testicular fibrosis and 
more connective tissue (135-137), DCN expression was readily detected by immunohistochemistry 
and qRT-PCR. These results led to the assumption that the DCN antibody employed is not sensitive 
enough to detect small amounts of DCN. 
Adult AROM+ males above the age of 2 - 3 months develop progressive age-dependent testicular 
fibrosis, inflammatory reactions and impaired spermatogenesis (135). This study revealed that these 
changes are correlated with high levels of testicular DCN. Accordingly, immunohistochemistry 
indicated strong DCN accumulation in the interstitial areas and to some degree also in the peritubular 
areas of AROM+ mice, a result in line with the general changes in infertile men. The peritubular 
region in human consists of several layers of peritubular cells whereas mice only possess one cell 
layer. Therefore fibrosis in the mouse testis occurs mainly in the interstitium and less in the peritubular 
region. Younger AROM+ mice, below the age of three months, were not included within this study 
because they are sexually immature and their testis resembles age-matched normal mouse testis. 
DCN expression during gonadal development is not explored, and in mice it may not play a role (158, 
159). In contrast, human and monkey testes show robust DCN expression. Since studies on DCN 
expression during ontogeny of human testis are not possible, it was investigated in postnatal testicular 
development of rhesus monkeys. The rhesus monkey, as a non-human primate possesses several layers 
of testicular peritubular cells, similar to men. Thus it appears to be an appropriate model for studies on 
the peritubular region. Immunohistochemistry using samples of monkeys of different ages, indicated 
that DCN expression in rhesus monkey testis decreases with sexual maturity. The degree of DCN 
staining of testicular connective tissue in the prepubertal monkey gonad is more pronounced than in 
the adult. What causes this physiological reduction of DCN during maturation remains to be shown. 
However, DCN is clearly inversely related to the degree of the activity of the testis, namely 
spermatogenesis, during testicular development.  
To summarize this point, the ECM proteoglycan DCN was found in the normal human and the non-
human primate testis. In mice DCN appears of low abundance, however in infertile AROM+ mice it 
becomes strongly expressed. Thus in infertile men and mice, the observed elevated DCN levels 
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correlate well with physiological or pathological states of infertility, irrespective of their cause. 
Furthermore, the present results of immunohistochemistry studies using testicular samples of rhesus 
monkeys of different ages indicated high DCN levels in the prepubertal, quiescent testes which are 
markedly decreased during sexual maturation and subsequently remained low even in the testes of old 
healthy animals. High levels of testicular DCN are inversely related to testicular functionality 
spermatogenesis, in health and disease. 
 
 
5.2 Steroid hormones do not influence DCN expression in HTPCs and HTPC-Fs 
Changes of testicular DCN expression during puberty may be related to the actions of steroid 
hormones, such as testosterone and estradiol, which are essential for normal testicular development as 
well as for spermatogenesis and thus male reproductive health. For instance, receptors for testosterone, 
ARs, are expressed in several testicular cell types, including peritubular cells, but which cell type 
mediates the specific androgen control of spermatogenesis remains contentious (19). Within the 
present study testosterone action on DCN levels was examined in normal peritubular cells and cells 
stemming from fibrotic testis. However, testosterone addition was not able to alter DCN mRNA levels 
in HTPCs and HTPC-Fs, at least under the experimental conditions used. This result leads to the 
assumption, that increased DCN levels in fibrotic testis and male sub- or infertility are not linked via 
testosterone. Further, this result goes in parallel with an other study, in which androgen action on 
proteoglycan biosynthesis in human vascular smooth muscle cells was tested (160). Treatment of 
vascular smooth muscle cells with testosterone at a concentration of 100 nM, the same concentration 
that was used on HTPC/HTPC-Fs, did not alter total DCN levels, but lead to increased [35S]sulfate 
incorporation into proteoglycans and increased GAG chain length, a process that results to a higher 
binding capacity to low density lipoproteins. By forming lipoprotein-proteoglycan complexes 
atherogenic low density lipoprotein accumulates and leads to cellular chemotaxis, including smooth 
muscle cell migration and monocyte adhesion. This possibility remains to be studied in HTPC/-Fs. 
Estradiol plays an important role in various physiological events, which are mediated via its nuclear 
estrogen receptors, ER-α and ER-β. 17β -estradiol, which was used in the present study, can interact 
with both receptors (203). The regulation of estradiol/testosterone ratio is important for male 
reproductive health. For instance, estradiol/testosterone levels are strongly elevated in male AROM+ 
mice which suffer from deranged spermatogenesis and infertility. Both human cellular models, 
employed in this study, express ER-α (unpublished data), but with regard to DCN 17β-estradiol, used 
at two concentrations, showed no influence on DCN regulation in HTPCs as well as in HTPC-Fs after 
6 h and 24 h. It is known from the literature that estrogens are able to regulate DCN synthesis in 
several tissues. Reports of the ovariectomized mouse uterus indicated a DCN downregulation by 
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estradiol after 6 h and 12 h (161). In addition, in human endometrium, where DCN is strongly 
expressed in the stromal areas, it is upregulated by estrogen (162). In sheep studies, estradiol was 
found to significantly upregulate DCN mRNA expression and in this manner, may act as a potential 
stimulator responsible for the increased DCN in the myometrium during parturition, whereas 
progesterone treatment had no effect on DCN mRNA abundance (163). 
To conclude this point, DCN mRNA expression was not altered by testosterone and estradiol, at least 
under the experimental conditions used within this study, but additional experiments employing 
different concentrations and time periods are required to fully exclude steroid hormone actions on 
DCN expression in HTPCs and HTPC-Fs. In case of androgens, the more potent androgen 
dihydrotestosterone, which has a three timer higher affinity for AR than testosterone, should be 
investigated with regard to DCN expression. 
 
 
5.3 DCN expression in HTPCs and HTPC-Fs is not affected by forskolin and prostaglandin 
15dPGJ2  
Forskolin is a known stimulator of intracellular cAMP signaling in many tissues. The ability of cAMP 
to regulate ECM gene expression in cultured rat chondrocytes has been shown previously (164). In the 
present study this possibility was tested with regard to DCN expression in HTPCs and HTPC-Fs. 
QRT-PCR results indicated that forskolin after a stimulation period of 4 h does not change DCN 
synthesis in HTPCs and in HTPC-Fs. This result is in line with reported data of bovine chondrocytes 
in which forskolin significantly increased aggrecan proteoglycan synthesis after 1 h and 5 h, but had 
no influence on DCN and collagen type I mRNA levels (165).  
Previous studies using HTPCs reported that metabolic activity was not affected by prostaglandins 
PGE2, PGF2α, PGD2 or PGJ2, but was stimulated by 15dPGJ2 after two days (134). Furthermore, the 
study showed that HTPC treatment with 15dPGJ2 for seven days reduced smooth muscle cell markers, 
but not fibroblast markers. 15dPGJ2 influences the smooth muscle cell phenotype and the contractility 
of human peritubular cells via reactive oxygen species. For this reason, in the present study was 
examined whether 15dPGJ2 is able to alter DCN expression in HTPCs or HTPC-Fs, thus changing 
them from a contractile to a secretory phenotype. The same culture conditions, stimulation periods and 
concentrations, as have been reported by Schell et al. (2010), were used to treat HTPCs and HTPC-Fs 
(134). Results indicated that, under the experimental conditions used, 15dPGJ2 did not influence DCN 
mRNA expression in both cell types, thus 15dPGJ2 via reactive oxygen species are not linked to DCN 
expression in peritubular cells. This result correlates with results of a previously reported study, in 
which a prostaglandin, namely PGE2, in equine tendon fibroblasts leads to increased gene expression 
of collagen type I, but not of DCN levels (166). 
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5.4 Immune cell products stimulate DCN expression in fibrotic testis 
The present study indicated that DCN production and secretion differs quantitatively in HTPCs and 
HTPC-Fs. The second distinct difference between both cell types, which was found in the present 
study, is their response to immune cell products. The major mast cell product, the protease tryptase, 
and a peptide agonist to the tryptase receptor (PAR-2), SLIGKV, increased DCN mRNA and protein 
levels in HTPC-Fs, but not in HTPCs. However, both cell types possess functional PAR-2 (132) and 
were shown within this study to responde in a similar manner to tryptase and SLIGKV with transient 
elevations of intracellular Ca2+. Regulation of DCN via PAR-2 activation, as observed in HTPC-Fs has 
not been reported yet, but the activation of a related receptor, PAR-1, by thrombin, has recently been 
revealed to result in increased DCN expression in vascular smooth muscle cells and to contribute to 
the development of atherosclerosis (167).  
The cytokine TNF-α is a product of macrophages and mast cells in mouse and human testes and is 
significantly increased in AROM+ mice and in infertile men (58, 137). In the present study the 
involvement of TNF-α in the regulation of DCN using HTPCs and HTPC-Fs was investigated. TNF-α 
was able to further stimulate the already increased DCN mRNA and secreted protein levels in HTPC-
Fs. Interestingly, in a recent study using a mouse model it was reported that DCN in turn enhances the 
release of cytokines like TNF-α by macrophages (168). Whether DCN produced by HTPC/HTPC-Fs 
can stimulate TNF-α production in macrophages in the human testis can only be speculated at that 
time and remains to be studied. 
The regulation of DCN gene expression has been shown to occur commonly via different cytokines, 
including TNF-α, expressed by inflammatory cells. For instance, IL-1 and IL-4 can induce DCN 
transcription in human fibroblasts (112) and TGF-β has been described as a potent regulator of DCN 
expression in several tissues (169, 170). In general, the regulation of DCN synthesis by cytokines is 
not well understood. For instance, TGF-β can stimulate or inhibit DCN expression, depending on the 
cell type and culture conditions (170, 171). With regard to TNF-α, the results of the present 
investigations indicating stimulation of DCN expression in HTPC-Fs upon stimulation with TNF-α, 
are in line with reported effects of TNF-α on DCN in isolated human chondrocytes (172). In contrast, 
in human dermal fibroblast cultures DCN expression decreased after TNF-α addition (110). 
Additionally, investigations in human lung fibroblasts showed an increase in total proteoglycan 
production upon stimulation with TNF-α, but especially DCN was downregulated (173). These 
different findings show that TNF-α influence on DCN expression varies from cell type to cell type and 
may be dependent on culture conditions, as well. 
Previous studies have dealt with regulatory actions of tryptase and the pro-inflammatory cytokine 
TNF-α in human peritubular cells. For instance, nerve growth factor (NGF), a secretory product of 
HTPCs, is upregulated by TNF-α in a dose- and time-dependent manner ((133) and Spinnler, 
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unpublished). Furthermore, the ability of TNF-α to induce the expression inflammatory markers, such 
as MCP-1, IL-6 and cyclooxygenase-2, has been shown in HTPCs (133). HTPC-Fs have not been 
investigated at that time. The response of HTPCs and HTPC-Fs to TNF-α, respectively tryptase, has 
been investigated with regard to GDNF expression (132). It has been found that neither HTPCs nor 
HTPC-Fs responded to one of the substances by altered production of GDNF. Therefore the increased 
sensitivity of DCN production in HTPC-Fs to tryptase and TNF-α is a distinct signature of these cells 
derived from patients with existing fertility problems.  
The reason for these differences in tryptase, respectively TNF-α, responses of HTPC and HTPC-Fs 
may be related to the altered microenvironment during testicular fibrosis, which includes the increased 
occurrence of tryptase and TNF-α producing mast cell and macrophages in the fibrotically remodeled 
peritubular walls (54, 58). Such a link is supported by a recently observed loss of smooth muscle cell 
markers in peritubular cells of sub- and infertile men (134). Cultured HTPCs and HTPC-Fs respond in 
different ways to immune cell products and thus appear to mimic the in vivo situations, indicating that 
these cells are excellent models for the study of the properties of peritubular cells from testes of 
normal and infertility patients. 
It has been reported that TNF-α preferentially uses the core protein of DCN as specific binding site 
(174), but it also binds to a certain degree to dermatan sulphate chains of DCN molecules. The 
mobility of these chains depends on the content of iduronic acid. Different tissues possess different 
levels of iduronic acid and Tufvesson and Westergren-Thorsson (2002) (174) therefore hypothesize 
that this causes a stronger DCN affinity for TNF-α in some tissues. Whether iduronic acid levels in the 
testis of infertile men differ from those in normal testis is not known, but cannot be completely 
excluded and could be a reason for different reactions of HTPCs and HTPC-Fs in DCN production 
and secretion upon TNF-α treatment. 
In several pathological processes such as asthma (175) and systemic sclerosis (176), TNF-α is known 
to be upregulated during early stages of inflammation, while DCN is downregulated. However, in 
progressive inflammation, when fibrotic lesions are formed, an upregulation has been observed. These 
findings lead to the assumption that increased TNF-α levels may induce DCN production during later 
stages of inflammation when fibrotic remodeling occurs (176). This may also be the case in human 
testis, where a TNF-α-induced DCN production in HTPC-Fs correlates with fibrotically remodeled 
testis and impaired spermatogenesis, while DCN was not altered by TNF-α in peritubular cells of 
healthy human testis. 
To summarize this point, tubular fibrosis is based on thickening of the peritubular region due to 
increased ECM production (57, 177). The present study shows that peritubular cells are involved in 
this process. Numbers of testicular mast cells and macrophages are increased in men suffering from 
infertility (54, 58, 150, 177). The present results therefore link immune cells, via their products 
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tryptase and TNF-α, to the increased production of the ECM component, DCN, during fibrotic 
conditions and impaired spermatogenesis. 
 
 
5.5 Mouse testicular fibroblasts 
A further aim of this study was to examine DCN expression and regulation in the testes of normal 
mice and infertile AROM+ males with fibrotically altered testes. Since TNF-α levels are elevated in 
AROM+ males, the regulation of DCN expression by TNF-α should be investigated in mouse 
fibroblasts.  
It was attempted to isolate peritubular cells of the testes of normal and AROM+ mice, using the same 
explant method as described for human cells. In some cultured samples myofibroblast-like cells that 
were immunocytochemically stained positive for SMA, were observed. However, cell yields were not 
sufficient and cells could not be propagated using the same methods as for HTPCs and HTPC-Fs.  
This might be due to differences between the mouse and the human system. The number of cell layers 
surrounding the seminiferous tubule is highly species-specific and rodents, in contrast to humans who 
have several, possess only one layer of peritubular cells. This might be a reason why results of 
examinations performed on rodents could not be completely assigned to the human system and for 
investigating how the particular constituents of the peritubular region are involved in the fibrotic 
thickening in the testis, the mouse is not the best model (145, 178, 179). 
In immunohistochemical experiments DCN deposits in AROM+ males were detected in fibrotically 
remodeled interstitial regions rather than in peritubular cells. Therefore in subsequent mouse testicular 
cell culture studies, interstitial fibroblasts were isolated. Although interstitial fibroblasts could be 
successfully isolated, cell numbers were not sufficient for additional studies. Cell culture conditions 
have to be optimized to successfully cultivate mouse testicular fibroblasts in a sufficient number in 
future experiments.  
At least experiments with mouse fibroblasts of a standard cell line, namely NIH/3T3 cells, revealed 
that DCN mRNA expression and protein levels are upregulated by TNF-α after 24 h respectively 72 h. 
Because of these results it is worth to further investigate TNF-α action on DCN expression in the 
mouse testis. 
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5.6 Expression of growth factor receptors in the human testis, known to be partners of DCN 
In the human testes DCN may be responsible for the assembly and/or protection of the ECM (121, 
180, 181). DCN action via a distinct “DCN receptor” has not been reported. Previous studies 
demonstrated that DCN is catabolized by receptor-mediated uptake and subsequent intralysosomal 
degradation (182-184). Previously, two endosomal proteins of 51 kDa and 26 kDa have described to 
interact with DCN core protein and to mediate DCN endocytosis. Endocytosis of SLRPs may also be 
mediated by additional receptors, namely the endocytic mannose receptor, EGFR and IGF-1R (185). 
Since a own receptor for DCN downstream signaling, does not exist, the investigations of the present 
study concentrated on DCN interference with growth factor receptors, namely EGFR and PDGFR. 
Roles of DCN may include a storage function for growth factors and a role as a ligand for growth 
factor receptors.  
As it is not possible to test any of these assumed functions of DCN in the human testis in health and 
disease in vivo, the examination of DCN interactions with growth factors/receptors expressed in 
primary cells (HTPC/HTPC-Fs) appear appropriate. In other cellular systems, DCN has been reported 
to interfere with signaling of several growth factors. One of the best-investigated growth factor 
receptor signaling systems that is affected by DCN is EGF and its receptos (121, 125, 126, 128). As 
previous studies in squamous carcinoma cells and tumor xenografts indicated, the proteoglycan 
inhibits EGFR by down-regulating its tyrosine kinase activity. DCN can act as a substrate, binding 
directly the EGFR kinase, subsequently inducing receptor dimerization, internalization and 
degradation (125, 126). In addition to EGF, PDGF signaling has been shown to be affected by DCN 
(117). In vascular smooth muscles cells, DCN binding to the ligand, namely PDGF, and the 
subsequent inhibition of PDGF-stimulated phosphorylation of PDGFR was demonstrated. 
Furthermore, in normal cells such as endothelial and renal cells, DCN affects different pathways via 
binding to IGF-1R, resulting in phosphorylation and activation, followed by receptor down-regulation 
(121-123, 186). In addition, it has been reported that VEGF (123) and HGF signaling (124) are further 
systems that were reported to be affected by DCN. The proteoglycan is a ligand to the respective RTK. 
In the present study receptors of the EGFR family (EGFR, ErbB2, ErbB3 and ErbB4), PDGFRs 
(PDGFR-α and PDGFR-β), IGF-1R, VEGFR and HGFR were examined and found to be present at 
mRNA level in HTPCs, as well as in HTPC-Fs. Nevertheless, studies performed concentrated 
especially on EGF/EGFRs and PDGF/PDGFRs as potential partners for DCN for several reasons. 
Firstly, EGFRs have been reported to be expressed in peritubular cells of the adult human testis (26). 
Expression of PDGFR in testicular peritubular cells has been shown in animal studies and the present 
study provides evidence for expression in the wall of seminiferous tubules in humans, as well. 
Secondly, a number of studies indicate that EGF and PDGF have distinct and important roles in the 
regulation of smooth muscle cells (117, 187-189), which may include testicular smooth muscle-like 
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peritubular cells (134). In fact several experiments performed within this study indicated a strong 
mitogenic role of EGF and PDGF in HTPCs, as well as in HTPC-Fs. 
While previous reports describe EGFR expression in peritubular myoid cells (26), the expression of 
PDGFR-α and PDGFR-β at this site of adult human testis is contentious. In a previous study, 
employing immunohistochemistry using testes samples from healthy adult men, no expression of 
PDGFRs in the peritubular regions has been found (33). Yet during development the receptors are 
present and PDGF is considered as an important regulator for peritubular cells (29, 117, 189, 190). 
Interestingly, in rat studies, it was demonstrated that peritubular cells of the adult males cease to 
express PDGFRs (191, 192). This phenomenon has been attributed to the shift from a synthetic to a 
contractile phenotype of peritubular cells during morphological and functional maturation of the testis 
(193). With regard to the present results, the attempt to localize EGFR and PDGFR proteins in the 
human peritubular wall by immunohistochemistry using commercial anti-sera failed, but laser 
microdissection and subsequent RT-PCR studies identified PDGFRs in the peritubular region, at least 
in biopsies from MA patients. In infertile men peritubular myoid cells may change their phenotype 
from a contractile to a secreting cell type. Whether expression of PDGFRs in adult human peritubular 
cells in vivo may occur again during initiation and progression of sub- or infertility is a point that 
requires additional studies. 
 
 
5.7 DCN can interact with EGF/EGFR and PDGF/PDGFR signaling in the human testis 
The present study found that exogenous DCN acutely induces alterations of intracellular Ca2+ levels in 
HTPC/-Fs, which occurred within seconds and lasted only for seconds. This observation is in line with 
findings in human squamous carcinoma cells (120) and hints to activation of growth factor receptors 
expressed by these cells. Accordingly, in other cellular systems DCN can act as a ligand to growth 
factor receptors, especially EGFRs, and can acutely activate them (121, 123-125). Therefore this 
possibility was examined for human testis by using HTPCs and HTPC-Fs. 
The concentration of DCN required for this action was higher than expected e.g. from the dissociation 
constant of DCN for EGFR (∼ 87 nM) (98). However HTPCs and HTPC-Fs constantly secrete DCN in 
concentrations of approximately 0.1-1 µg/ml, which may thus constantly downregulate growth factor 
receptors. Therefore higher concentrations of at least 10 µg/ml are required in the experimental 
setting. With regard to the literature, even a lower DCN concentration was used to treat HTPCs and 
HTPC-Fs within the present investigations, than for studies in rabbit aortic smooth muscle cells where 
30 µg/ml have been used (117). In addition, for measurements of intracellular Ca2+ levels, freshly 
trypsinized (12 h before) HTPCs and HTPC-Fs were used in each experiment to minimize a high DCN 
level caused by their own secretion. Interestingly, if cells were cultured for longer time periods (about 
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4 - 5 days), DCN induced Ca2+ signals were not observed. In support of the assumption that DCN 
downregulates growth factor signaling, pretreatment of freshly trypsinized HTPC/-Fs with exogenous 
DCN for 24 h abolished the ability of DCN, EGF and PDGF but not of histamine (55), to elevate 
intracellular Ca2+ levels. This result is in line with observations in carcinoma cells, in which DCN 
markedly attenuates the mobilization of intracellular Ca2+ stores, a key pathway in EGFR- and 
PDGFR-mediated signaling (32, 126).  
 
Interactions of DCN with growth factors or activation of their RTKs have not been studied in 
HTPC/HTPC-Fs yet, but transient elevation of intracellular Ca2+ evoked by DCN, in a similar way as 
by EGF and PDGF, led to the suggestion that DCN interferes with testicular EGFR and PDGFR 
signaling. To study the mechanisms of DCN action and test this assumption an analysis of 
phosphorylation of growth factor receptor was performed. As expected (125), DCN directly interferes 
with EGFRs and causes phosphorylation of EGFR in HTPCs and HTPC-Fs, a result that was found in 
an initial screening for RTK phosphorylation using a commercial protein array. Western blot 
experiments confirmed these data. Furthermore a strong phosphorylation of EGFR became evident in 
a positive control, in which EGF was used for cell treatment. In contrast to EGFR, initial protein array 
suggested a very low phosphorylation of PDGFR-β by DCN. In subsequent Western blot experiments 
a DCN induced phosphorylation of PDGFR-β was not observed, but a strong phosphorylation of the 
receptor by PDGF-BB, which was used as a positive control because it is known to bind all PDGFR 
isoforms and dimerizes α- and β-receptors into different configurations (PDGFR-αα, -αβ,-ββ) (29), 
became evident. This result is in line with the apparent ability of DCN to interfere with the ligand 
rather than to affect phosphorylation of this receptor (117, 194). Screening for RTK phosphorylation 
in HTPCs indicates furthermore, that DCN may be a ligand for HGFR, while VEGR and IGF-1R, at 
least under the experimental conditions used, may not be affected by DCN. A final conclusion cannot 
be drawn however, because the binding of DCN occurs with different affinities to different receptors, 
and thus both expression patterns of growth factor receptors and the concentrations of available DCN 
are of importance (98). 
Less is known about the function of HGF within the human testis, but evidence is emerging that it may 
regulate somatic cell function, including Leydig cell steroidogenesis. Changes in the cellular origin of 
HGF and c-met during testicular development suggest that HGF may contribute to regulate testicular 
morphogenesis and differentiation (195). HGF/HGFR signaling and DCN interference with this 
signaling system in HTPC and HTPC-Fs represents an interesting topic, that remains to be studied.  
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5.8 Consequences of DCN interference with growth factor signaling 
In the present study special emphasis was put on the investigation of the consequences of the 
interference of DCN with EGF/EGFR and PDGF/PDGFR systems in HTPCs and HTPC-Fs.  Results 
of several experiments measuring caspase-3/7 activity, ATP levels and cell proliferation indicated that 
in an experimental situation chronic actions of DCN might unfold only when growth factors are 
present. Results of DAPI, CASY, ATP and caspase-3/7 measurements indicated that DCN addition 
alone exerted no effect on mitosis and viability of the HTPCs and HTPC-Fs. These results are in line 
with e.g. studies in human airway smooth muscle cells, in which exogenous DCN affected neither cell 
proliferation, nor apoptosis (190). This observed lack of DCN action after 24 h also indicates that an 
initial activation, evidenced by increased Ca2+ or phosphorylation of growth factor receptors, is 
followed by a DCN induced down-regulation of growth factor receptor signaling (117, 125, 126, 194).  
In previous studies, EGF and PDGF were shown to stimulate processes such as cell proliferation, 
differentiation and migration (29, 117, 151). In the present investigations EGF and PDGF evoked 
strong proliferative responses in HTPC and HTPC-Fs. These effects were observed in DAPI 
experiments after 24 h but not at earlier times (6 h or 18 h). Cellular ATP levels and mitotic events 
were significantly increased after 24 h EGF or PDGF-BB treatment. Increased cell numbers were 
found after four days of stimulation with EGF or PDGF. Importantly, the addition of DCN at the same 
time as the growth factor, significantly reduced these growth factor actions after 24 h or four days, 
results that clearly indicate that DCN is a factor that when present is able to interfere with growth 
factor signaling and actions. These finding are in accordance with previous reported animal study 
results. Pretreatment of rabbit aortic smooth muscle cells with DCN significantly inhibited PDGF-
stimulated cell migration and proliferation (117).  
It has been previously reported that testicular peritubular cells of the rat, when chronically stimulated 
with PDGF, undergo cellular hypertrophy and produce increased levels of smooth muscle cells  
markers, e.g. SMA (151, 191). Peritubular smooth muscle cells from the rat testis in primary serum-
free cultures undergo contraction and subsequent hypertrophy in response to PDGF-BB (134, 151). In 
the human cellular model, investigated in the present study, PDGF-BB treatment did not alter the cell 
size of HTPCs or HTPC-Fs. This might be due to different culture conditions, but also the distinct 
differences between the human and the animal model may be responsible. 
PDGF-BB treatment did not lead to hypertrophy, but resulted in elevations of SMA in HTPCs and 
HTPC-Fs, a well-known differentiation marker of myofibroblasts (196). In both cell types SMA 
mRNA levels and cell proliferation were found to be increased, indicating the important role of PDGF 
for differential processes in human peritubular cells. Interestingly, the PDGF induced elevation of 
SMA level could be blocked by DCN. DCN alone did not affect SMA levels in HTPCs and HTPC-Fs 
after four days. A recent report about human myofibroblast cell lines indicated that increased DCN 
levels were accompanied by suppression of SMA expression after six days, whereas knock down of 
5. DISCUSSION 73 
DCN expression lead to increased expression of SMA (196). These findings are in contrast to results 
in the present study and may be due to differences in the cellular systems, but possibly DCN has the 
same effect on SMA expression in HTPC/HTPC-Fs after six days, a fact that remains to be studied. 
The inhibitory effect of the proteoglycan on EGF and PDGF-stimulated HTPC/-Fs functions was not 
due to cell apoptosis. These observations are in line with a study performed by Nili et al. (2003) (117), 
which demonstrated also no evidence of active caspase-3 in DCN-treated rabbit aortic smooth muscle 
cells. In contrast, in carcinoma cells studies DCN was reported to inhibit cancer growth and 
metabolism by enhancing apoptosis via caspase-3 activation and reducing the mitotic index, two 
events that have been associated with the suppression of EGFR signaling (197). These differences may 
be due to the distinct microenvironment in which carcinoma and HTPC/-Fs occur. 
In view of the mechanism how DCN mediates its inhibitory effects on EGFR and PDGFR signaling in 
HTPCs and HTPC-Fs, the phosphorylation experiments of the present study revealed that in case of 
EGFR, DCN directly interacts with this RTK and thus may block EGF binding to its receptor. With 
regard to PDGFR signaling in human peritubular cells, DCN does not interact with the RTK, but may 
bind directly its ligand and thus regulate its availability to the receptor. 
In addition, it is worth mentioning that the present investigation revealed DCN staining also in the 
interstitial compartment of the human testis and that several growth factor receptors have been 
described in Leydig cells (33, 192). Thus, the ability of DCN to interfere with growth factor actions in 
the human testis may extend to Leydig cells and others, as a well.  
The possible regulation and signaling pathways of testicular DCN, investigated in the present study, 
are summarized in Figure 5-1. 
 
 
Figure 5-1: Overview of DCN regulation and signaling in the human testis. Human peritubular cells express 
receptors for TNF-α (TNFR-1/2) and tryptase (PAR-2). Both immune cell products lead to increased DCN 
production and secretion in HTPC-Fs, but not in HTPCs. DCN can interfere with EGF and PDGF signaling in 
HTPC/-Fs. Increased DCN levels in infertile men, which are a consequence of actions of immune cell derived 
TNF-α and tryptase, may imbalance paracrine signaling in the human testis. 
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5.9 Actions of imatinib mesylate in HTPCs 
The present study revealed that DCN is emerging as an endogenous ligand/antagonist for growth 
factor signaling in peritubular cells of the human testis. In addition the effect of an exogenous ligand 
for growth factor receptors, namely the drug imatinib mesylate, in the normal human testis was 
investigated using HTPCs. Imatinib is a small molecular analog of ATP that inhibits the Abelson 
kinase, PDGFR-α, PDGFR-β and c-kit tyrosine kinases. This drug is used to treat patients with 
chronic myeloid leukemia (142, 144, 198, 199).  
Previous studies demonstrated that imatinib, through its ability to inhibit PDGFR signaling, interferes 
with development of Leydig and peritubular cells during postnatal testicular ontogeny in the rat (145). 
Within the present investigations stimulations of HTPCs with different concentrations of imatinib for 
24 h indicated a dose-dependent decrease of cellular viability of adult peritubular cells in the human 
testis. However, concentrations of 10 µM or lower did not disturb viability of HTPCs, but were able to 
block PDGF induced proliferative and mitogenic actions, when both substances were added at the 
same time. 
Interestingly, first clinical case studies in patients suffering from systemic sclerosis demonstrated that 
imatinib, by its ability to block the pro-fibrotic Abelson kinase and PDGFR, reduces synthesis and 
accumulation of ECM in lesional skin (200, 201). The same work group found the reduction of 
established skin fibrosis in an animal model (202). The ability of imatinib to possibly reduce fibrosis 
in the testis remains to be examined. 
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6. SUMMARY 
Testicular peritubular cells and the ECM of the walls of the seminiferous tubules were barely 
investigated. The aim of the present study was to characterize the wall of the tubules with regard to the 
ECM proteoglycan DCN. In addition the regulation and function of DCN were studied. 
The expression of this proteoglycan during states of infertility and development was examined in 
human, rhesus monkey and rodent testes. While DCN mRNA was readily found in the testis of all 
examined species, DCN protein was only detected in peritubular and interstitial areas of adult human 
and monkey testes. In human, immunohistochemistry indicated that this proteoglycan, which is 
normally produced in low levels by testicular peritubular cells, is strongly increased in testicular 
biopsies of MA, GA and SCO syndrome patients. Furthermore DCN was almost undetectable in adult 
rodents, but was highly expressed in the testes of infertile, aromatase-overexpressing transgenic mice 
(AROM+). Immunohistochemical staining of testicular samples of rhesus monkeys of different ages 
indicated that levels and sites of expression of testicular DCN change also during postnatal maturation. 
In the non-human primate DCN is associated with the abundant connective tissue of the interstitial 
areas in the postnatal through prepubertal phases. In adult and old monkeys the DCN pattern was 
similar to the one in normal human testes. Thus levels of DCN inversely correlate with testicular 
functionality. 
Impaired spermatogenesis in men is frequently accompanied by accumulation of tryptase-positive 
mast cells in the testis. One aim of this study was the investigation of testicular DCN expression, 
regulation and actions using cultured primary human testicular peritubular cells (HTPCs), which stem 
from testes with normal spermatogenesis and corresponding cells isolated from men suffering from 
impaired spermatogenesis and existing testicular fibrosis (HTPC-Fs). QRT-PCRs, Western blotting 
and ELISA measurements revealed that HTPC-Fs synthesize and secrete higher quantities of DCN 
than HTPCs, a finding, mirroring the situation in vivo. In contrast to HTPCs, HTPC-Fs also responded 
to immune cell products, namely mast cell tryptase and TNF-α, by further increased DCN production 
and secretion. The data indicate that the increased amount of DCN, found in human male infertility is 
a consequence of actions of immune cell-derived tryptase and TNF-α. 
As DCN is known from other tissues to interfere with growth factor signaling, this possibility was 
investigated in HTPCs and HTPC-Fs. RT-PCR studies revealed that both cell types express receptor 
tyrosine kinases, namely the EGFR family (EGFR, ErbB2, ErbB3, ErbB4), PDGFRs (PDGFR-α and 
PDGFR-β), VEGFR, IGF-1R and HGFR which are known targets for DCN action. The acute abilities 
of DCN to transiently increase intracellular Ca2+ levels in both cell types, lead to the assumption that 
DCN might act via one or more of these growth factor receptors. Measurements of ATP levels, cell 
numbers and mitotic events after DAPI staining revealed strong mitogenic reponses in HTPC/-Fs upon 
stimulation with human recombinant EGF or PDGF. These actions could be blocked in the presence of 
DCN. Importantly, DCN alone did not influence viability and mitosis in both cell types. 
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Phosphorylation studies revealed a DCN caused phosphorylation of EGFR, but not of PDGFR-β. 
Thus, DCN is a factor able to influence growth factor signaling in human testicular peritubular cells. 
The general or focal deposits of DCN may imbalance paracrine signaling of the testis in health and 
disease. 
In conclusion, the results of this study using human testicular cells from normal and sub/-infertile men, 
provide insights into the regulation and the roles of DCN as a factor involved in the paracrine 
signaling in the testis. In the testis of men suffering from infertility immune cell numbers are increased 
and via their products TNF-α and tryptase can act as regulators of DCN production by peritubular 
cells. Hence, the results indicate that the functions of testicular MCs may be intrinsically linked to 
changes of the testis of men with impaired spermatogenesis. 
Furthermore, the data indicate that in testes of men with deranged spermatogenesis, the typical fibrotic 
changes include increased amounts of DCN, which may consequently imbalance testicular growth 
factor signaling via direct actions or by serving as a reservoir of growth factors. Although increased 
levels of DCN in HTPC-Fs were observed, no difference between HTPCs and HTPC-Fs with regard to 
Ca2+ increase, mitotic activity and phosphorylation of EGFR and PDGFR-β could be detected. Despite 
this, the possibility that increased DCN amounts upset the balance of normal testicular function, 
including growth factor actions, cannot be excluded.  
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7. ZUSAMMENFASSUNG 
 
Testikuläre peritubuläre Zellen und die ECM in der Wand der Tubuli seminiferi wurden bisher wenig 
untersucht. Aus diesem Grund war das Ziel der vorliegenden Studie die Charakterisierung der 
Tubuliwand in Bezug auf DCN, ein Proteoglykan der ECM. Des Weiteren wurden die Regulation und 
Funktion von DCN untersucht.  
Die Expression dieses Proteoglykans bei Infertilität und während der Entwicklung wurde im humanen 
Hoden und im Hoden von Rhesusaffen und Nagetieren untersucht. Obwohl DCN mRNA im Hoden 
aller untersuchten Spezies gefunden wurde, konnte das DCN Protein nur in pertitubulären und 
interstitiellen Bereichen im Hoden erwachsener Menschen und Affen detektiert werden. Beim 
Menschen ließen immunhistochemische Methoden erkennen, dass dieses Proteoglykan, das 
normalerweise in kleinen Mengen von testikulären, peritubulären Zellen produziert wird, in 
testikulären Biopsien von Patienten mit gemischter Atrophie, Keimzellarrest und Sertoli-cell-only-
Syndrom vermehrt vorkommt. Darüber hinaus war DCN in adulten Nagetieren fast undetektierbar, 
aber im Hoden infertiler, Aromatase-überexprimierender, transgener Mäuse (AROM+) war es stark 
exprimiert. Immunhistochemische Färbung von testikulären Proben von Rhesusaffen verschiedenen 
Alters zeigte, dass die Mengen und Orte testikulärer DCN Expression auch während der postnatalen 
Entwicklung variieren. Im nicht-humanen Primaten ist DCN, in der postnatalen und durch die 
präpubertäre Phase hindurch, mit dem mächtigen Bindegewebe der interstitiellen Regionen assoziiert. 
Das DCN Muster im Hoden erwachsener und älterer Affen war dem im normalen humanen Hoden 
ähnlich. Demzufolge korrelieren die DCN Mengen invers mit der Funktionalität des Hodens.  
Die beeinträchtigte Spermatogenese bei Männern geht oft mit der Anhäufung von Tryptase-positiven 
Mastzellen im Hoden einher. Ein Ziel dieser Studie war die Untersuchung der testikulären DCN-
Expression, -Regulation und -Wirkung, an kultivierten primären humanen testikulären peritubulären 
Zellen (HTPCs), die von Hoden mit normaler Spermatogenese stammen und entsprechenden Zellen, 
die von Männern, die unter gestörter Spermatogenese und testikulärer Fibrose leiden, isoliert wurden 
(HTPC-Fs).  
QRT-PCRs, Western blots und ELISA Messungen zeigten, dass HTPC-Fs mehr DCN synthetisieren 
und sezernieren als HTPCs, eine Entdeckung, die die Situation in vivo widerspiegelt. Im Gegensatz zu 
HTPCs, antworten HTPC-Fs auf die Produkte von Immunzellen, nämlich Mastzell-Tryptase und TNF-
α, durch weitere DCN Produktion und Sekretion. Die Daten zeigen, dass die erhöhte DCN Menge, die 
bei humaner Infertilität gefunden wird, eine Konsequenz der Tryptase- und TNF-α-Wirkung ist. 
Da aus Untersuchungen an anderen Geweben bekannt wurde, dass DCN mit Wachstumsfaktor-
Signalwegen interagieren kann, wurde dies in HTPCs und HTPC-Fs untersucht. RT-PCR Studien 
zeigten, dass beide Zelltypen RTKs, nämlich EGFRs (EGFR, ErbB2, ErbB3, ErbB4), PDGFRs 
(PDGFR-α und PDGFR-β), VEGFR, IGF-1R und HGFR, die bekannte Ziele der DCN Wirkung sind, 
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besitzen. Die Fähigkeit von DCN kurzzeitig die Ca2+-Spiegel in beiden Zelltypen zu erhöhen führte zu 
der Annahme, dass DCN möglicherweise über einen oder mehrere dieser Wachstumsfaktorrezeptoren 
wirkt. Durch Messungen des ATP Gehalts, der Zellzahl und der Mitosen nach DAPI Färbung wurden 
nach Stimulation mit humanen, rekombinanten EGF oder PDGF starke mitogene Antworten in 
HTPC/-Fs aufgedeckt. Diese Wirkungen konnten durch die Anwesenheit von DCN inhibiert werden. 
Von besonderer Wichtigkeit ist hierbei, dass DCN allein keinen Einfluss auf die Viabilität und die 
Mitose in beiden Zelltypen hatte. Phosphorylierungsstudien zeigten, dass DCN den EGFR, aber nicht 
den PDGFR-β, phosphoryliert. Demzufolge, ist DCN ein Faktor, der Wachstumsfaktor Signalwege in 
humanen testikulären Zellen beeinflussen kann. Die generellen oder fokalen DCN-Anhäufungen 
bringen möglicherweise die parakrine Signalübermittlung des Hodens aus dem Gleichgewicht. 
Zusammenfassend geben die Ergbnisse dieser Untersuchungen an humanen testikulären Zellen von 
normalen und sub-/infertilen Männern Einblick in die Regulation und die Rolle von DCN als ein 
Faktor, der in parakrine Signalwege im Hoden involviert ist. Im Hoden von Männern die unter 
Infertilität leiden ist die Anzahl der Immunzellen erhöht, die über ihre Produkte, TNF-α and Tryptase, 
als Regulatoren der DCN Synthese in peritubulären Zellen dienen. Demzufolge zeigen die Ergebnisse, 
dass die Funktionen von testikulären Mastzellen tatsächlich mit Veränderungen im Hoden von 
Männern mit beeinträchtigter Spermatogenese in Verbindung stehen. 
Ferner weisen die Daten darauf hin, dass im Hoden von Männern mit gestörter Spermatogenese, die 
typischen fibrotischen Veränderungen erhöhte Mengen an DCN enthalten. Dieses bringt 
möglicherweise direkt oder indem es als Speicher für Wachstumsfaktoren dient, das testikuläre 
Wachstumsfaktor-Signaling aus dem Gleichgewicht. Obwohl erhöhte DCN Mengen in HTPC-Fs 
beobachtet wurden, konnten keine Unterschiede zwischen HTPCs und HTPC-Fs im Hinblick auf die 
Erhöhung des intrazellulären Ca2+-Spiegel, der Wirkung auf die Mitose und in der Phosphorylierung 
von EGFR und PDGFR-β aufgedeckt werden. Trotzdem kann die Möglichkeit, dass erhöhte DCN 
Mengen das Gleichgewicht normaler Hodenfunktion, einschließlich der Wachstumsfaktor-Signal-
übertragung stören, nicht ausgeschlossen werden.  
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10. APPENDIX 
10.1 Primer 
Table 10-1: Overview of primers, their GenBank accession numbers, product sizes and annealing 
temperatures. 
 
Target Sequence (5´-3´) GenBank 
Accession no. 
Amplicon  
(bp) 
Annealing 
temperature 
(C°)/cycles 
Calponin 
  forward 
  reverse 
 
CGA AGA CGA AAG GAA ACA AGG 
GCT TGG GGT CGT AGA GGT G 
NM_001299.4 183 50/30 
CD90 
  forward 
  reverse 
 
AGC ATC GCT CTC CTG CTA ACA 
CTC GTA CTG GAT GGG TGA ACT 
NM_006288.3 138 61/30 
Collagen IV 
  forward 
  reverse 
 
CTC CGC ACT CAA GAG GCT C 
AGA CGC TCT GGG CGA GGA A 
NM_001846.2 352 62/35 
Cyclophilin 
  forward 
  reverse 
 
CTC CTT TGA GCT GTT TGC AG 
CAC CAC AGT CTT GCC ATC C 
NM_006347 325 56/25 
DCN 
  forward 
  reverse 
 
GGA ATT GAA AAT GGG GCT TT 
GCC ATT GTC AAC AGC AGA GA 
NM_001920 221 59/35-39 
DCN nested 
  forward 
  reverse 
 
CAC CAG CAT TCC TCA AGG TC 
TCA ATC CCA ACT TAG CCA AA 
NM_001920 122 59/35 
EGFR 
  forward 
  reverse 
 
CAG CGC TAC CTT GTC ATT CA 
TGC ACT CAG AGA GCT CAG GA 
NM_005228.3 195 56/35-39 
EGFR nested 
  forward 
  reverse 
CAT TCA GGG GGA TGA AAG AA 
ATG AGG TAC TCG TCG GCA TC 
NM_005228.3 114 56/35 
ErbB2 
  forward 
  reverse 
AGT ACC TGG GTC TGG ACG TG 
CTG GGA ACT CAA GCA GGA AG 
NM_001005862 194 58/35 
ErbB3 
  forward 
  reverse 
GCC AAT GAG TTC ACC AGG AT 
ACG TGG CCG ATT AAG TGT TC 
NM_001982 243 54/35 
ErbB4 
  forward 
  reverse 
TTT CGG GAG TTT GAG AAT GG 
GAA ACT GTT TGC CCC CTG TA 
NM_001042599 183 54/35 
HGFR 
  forward 
  reverse 
CAG GCA GTG CAG CAT GTA GT 
GAT GAT TCC CTC GGT CAG AA 
NM_000245 201 56/35 
IGF-1R 
  forward 
  reverse 
 
AAC CCC AAG ACT GAG GTG TG 
TGA CAT CTC TCC GCT TCC TT 
NM_000875 172 57/35 
Mouse DCN 
  forward 
  revese 
TGA GCT TCA ACA GCA TCA CC 
AAG TCA TTT TGC CCA ACT GC 
NM_001190451 181 60/35 
MYH11 
  forward 
  reverse 
GGA CGA CCT GGT TGT TGA TT 
GTA GCT GCT TGA TGG CTT CC 
NM_002474.2 656 60/35 
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10.2 Chemicals 
Table 10-2: List of used chemicals, manufacturers and cities. 
 
Reagent Manufacturer City 
Acrylamide solution 30 % AppliChem Darmstadt, Germany 
Agarose Metaphor Biozym Oldendorf, Germany 
Ammonium persulfate Merck Darmstadt, Germany 
Aprotinin Sigma Aldrich Deisenhofen, Germany 
Boric acid Sigma Aldrich Deisenhofen, Germany 
Bromophenol blue Serva Heidelberg, Germany 
Bovine serum albumin PAA Cölbe, Germany, Germany 
CASYclean InnovatisAG Reutlingen, Germany 
CASYton InnovatisAG Reutlingen, Germany 
Chloroform Merck Darmstadt, Germany 
Citric acid Roth Karlsruhe, Germany 
Collagenase I Sigma Aldrich Deisenhofen, Germany 
Decorin, human recombinant Immundiagnostik Bensheim, Germany 
Decorin, from bovine articular cartilage Sigma Aldrich Deisenhofen, Germany 
15-deoxy-Δ-PGJ2 Cayman Chemicals Ann Arbor, MI, USA 
DEPC-treated water Invitrogen Karlsruhe, Germany 
Dimethylsulfidoxide Sigma Aldrich Deisenhofen, Germany 
dNTPs Promega GmbH Mannheim, Germany  
dNTPs (dATP, dCTP, dTTP, dGTP) Peqlab Erlangen, Germany 
Dipotassium phosphate Merck Darmstadt, Germany 
Disodium phosphate Merck Darmstadt, Germany 
     
PDGFR-α  
  forward 
  reverse 
GGG GAG AGT GAA GTG AGCTG 
TCC CAT TAA AGC GCT GTC TG 
NM_006206 391 56/35 
PDGFR-α  
nested 
  forward 
  reverse 
AGA AAA CAA CAG CGG CCT TT 
CTA CAT CTG GGT CTG GCA CA 
NM_006206 158 56/35 
PDGFR-β  
  forward 
  reverse 
GTG ACG TAC TGG GAG GAG GA 
TTA AAG GGC AAG GAG TGT GG 
NM_002609 155 58/35 
PDGFR-β  
semi-nested 
  forward 
  reverse 
AGC AGG AGT TTG AGG TGG TG 
TTA AAG GGC AAG GAG TGT GG 
NM_002609 136 58/35 
RPL19 
  forward 
  reverse 
 
AGG CAC ATG GGC ATA GGT AA 
CCA TGA GAA TCC GCT TGT TT 
NM_000981 199 58/39 
SMA 
  forward 
  reverse 
GTG ACC TCA CGG TGT TGA TT 
CCA ATG GTG ATA ACC TGC CC 
NM_006347 205 61/30 
VEGFR 
  forward 
  reverse 
 
GTG ACC AAC ATG GAG TCG TG 
TGC TTC ACA GAA GAC CAT GC 
NM_002253 218 57/35 
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Dithiothreitol (DTT) 0.1 M Invitrogen Karlsruhe, Germany 
DMEM high Glucose, w Phenol red w L-Glutamine PAA Cölbe, Germany 
DMEM high Glucose, w/o Phenol red w L-
Glutamine 
PAA Cölbe, Germany 
DMEM/Ham`s F12,  PAA Cölbe, Germany 
EGF, human recombinant New England Biolabs Frankfurt, Germany 
Entellan Merck Darmstadt, Germany 
17β-Estradiol Sigma Aldrich Deisenhofen, Germany 
Ethanol 100 % p. a.  Roth Karlsruhe, Germany 
Ethidium bromide Sigma Aldrich Deisenhofen, Germany 
Ethylene diaminetetraacetic acid (EDTA) Sigma Aldrich Deisenhofen, Germany 
Ethylene glycol tetraacetic acid (EGTA) Sigma Aldrich Deisenhofen, Germany 
Fetal calf serum PAA Cölbe, Germany 
5x First strand buffer Invitrogen Karlsruhe, Germany 
Fluo-4, acetoxy-methylester Molecular 
Probes 
Eugene, OR, USA 
Formaldehyde Sigma Aldrich Deisenhofen, Germany 
Forskolin Sigma Aldrich Deisenhofen, Germany 
Full Range Mol Weight Marker Rainbow GE Healthcare Bio-
Sciences 
Munich, Germany 
Glycerol Merck Darmstadt, Germany 
Glycine Applichem Darmstadt, Germany 
GoTaq DNA-Polymerase Promega GmbH Mannheim, Germany 
5x Green GoTaq-Reaction-Buffer Promega GmbH Mannheim, Germany 
Ham`s F12 PAA Cölbe, Germany 
Hydrogen peroxide 30 % Sigma Aldrich Deisenhofen, Germany 
Imatinib mesylate Glivec, Novartis 
Pharma 
Basel, Switzerland 
Isopropyl alcohol Apotheke, Klinikum 
Rechts der Isar 
München, Germany 
Leupeptin Sigma Aldrich Deisenhofen, Germany 
Magnesium chloride Sigma Aldrich Deisenhofen, Germany 
MassRuler Low Range DNA Ladder Fermentas St.-Leon-Rot, Germany 
2-Mercaptoethanol Sigma Aldrich Deisenhofen, Germany 
Methanol Roth Karlsruhe, Germany 
M-Mul VRT Rnase Finnzymes Oy Espoo, Finland 
Monosodium phosphate Merck Darmstadt, Germany 
Monopotassium phosphate Merck Darmstadt, Germany 
Normal serum donkey Sigma Aldrich Deisenhofen, Germany 
Normal serum goat Sigma Aldrich Deisenhofen, Germany 
Nuclease eliminator MoBiTec Göttingen, Germany 
Paraformaldehyde Merck Darmstadt, Germany 
PDGF-AA, human New England Biolabs Frankfurt, Germany 
PDGF-BB, human Sigma Aldrich Deisenhofen, Germany 
Penicillin PAA Cölbe, Germany 
pH Calibration standard pH 4/7/10 Roth Karlsruhe, Germany 
Phenylmethanesulfonylfluoride (PMSF) Invitrogen Karlsruhe, Germany 
Phosphate buffered saline Biochrom  
Pipes Sigma Aldrich Deisenhofen, Germany 
Ponceau S Sigma Aldrich Deisenhofen, Germany 
Precission Plus Protein Kaleidoscope Standard Bio-Rad München, Germany 
Random hexamer primer (300 ng/µl) Finnzymes Oy Espoo, Finland 
RNAsin Plus Rnase Inhibitor 40 units/µl Promega GmbH Mannheim, Germany 
RPMI medium 1640, ready mix PAA Cölbe, Germany 
Saccharose Merck Darmstadt, Germany 
Skin ß Tryptase, human recombinant Promega GmbH Mannheim, Germany 
Smooth muscle cell growth medium 2 PromoCell Heidelberg, Germany 
Sodium chloride Merck Darmstadt, Germany 
Sodiumdodecylsulfate (SDS) Sigma Aldrich Deisenhofen, Germany 
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Sodium orthovanadate Sigma Aldrich Deisenhofen, Germany 
Super Script II  Invitrogen Karlsruhe, Germany 
Streptomycin PAA Cölbe, Germany 
N,N,N’,N’-Tetramethylendiamin (TMED) 100 % Bio-Rad München, Germany 
TNF-α, human Sigma Aldrich Deisenhofen, Germany 
TNF-α, mouse New England Biolabs Frankfurt, Germany 
Trichloroacetic acid Roth Karlsruhe, Germany 
Tris Base Sigma Aldrich Deisenhofen, Germany 
Trisodium citrate Roth Karlsruhe, Germany 
TRIsure Bioline GmbH  Luckenwalde, Germany 
Triton® X-100 Bio-Rad München, Germany 
Trypsin-EDTA PAA Cölbe, Germany 
Tween 20 Sigma Aldrich Deisenhofen, Germany 
Xylene 99 % Roth Karlsruhe, Germany 
 
 
10.3 Antibodies 
Table 10-3: Summary of antibodies, manufacturers, order numbers and cities. 
 
Antibody Manufacturer Order number City 
Biot. Goat anti rabbit Dianova 111-065-144 Hamburg, Germany 
Biot. Donkey anti goat Dianova 705-066-147 Hamburg, Germany 
Pox goat anti rabbit Dianova 111-035-144 Hamburg, Germany 
Pox goat anti mouse Dianova 115-036-003 Hamburg, Germany 
Pox rabbit anti goat Dianova 305-036-003 Hamburg, Germany 
β-Actin mouse monoclonal Sigma Aldrich A5441 Deisenhofen, Germany 
Anti-Actin alpha smooth 
muscle monoclonal antibody, 
clone 1A4  
Sigma Aldrich A5228 Deisenhofen, Germany 
CD90 mouse monoclonal, 
clone AS02 
Dianova DIA 100 Hamburg, Germany 
Collagen type I, mouse 
monoclonal, clone I-8H5 
Acris Antibodies AF5610-1 Hiddenhausen, Germany 
Collagen type IV, mouse 
monoclonal, clone IV-4H12 
Acris Antibodies AF5910 Hiddenhausen, Germany 
DCN goat monoclonal 
antibody 
R&D systems AF143 Wiesbaden-Nordenstadt, 
Germany 
p44/p42 MAPK (Erk1/1) 
monoclonal antibody, rabbit 
Cell Signaling 
Technology, New 
England Biolabs 
9102 Frankfurt am Main, Germany 
Phospho-p44/p42 MAPK 
monoclonal antibody, mouse 
Cell Signaling 
Technology, New 
England Biolabs 
9106 Frankfurt am Main, Germany 
PDGFR-α Santa Cruz 
Biotechnology 
sc-338 Santa Cruz, CA, USA 
PDGFR-β Santa Cruz 
Biotechnology 
sc-339 Santa Cruz, CA, USA 
Anti-Phospho-PDGFR-β 
(Y1021) antibody, rabbit 
R&D systems AF2316 Wiesbaden-Nordenstadt, 
Germany 
Anti-Phospho-EGFR (Y1173) 
antibody, rabbit 
R&D systems AF1095 Wiesbaden-Nordenstadt, 
Germany 
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10.4 Kits and assays 
Table 10-4: List of employed commercial kits and assays, their manufacturer and origin. 
 
Kit/Assay Manufacturer City 
Caspase-Glo 3/7 Assay Promega GmbH Mannheim, Germany 
CellTiter-Glo® Luminescent Cell Viability 
Assay 
Promega GmbH Mannheim, Germany 
DAB-Tablet Set Sigma Aldrich Deisenhofen, Germany 
DC Protein Assay Bio-Rad München, Germany 
Deoxyribonuclease I, Amplification Grade Invitrogen 
 
Espoo, Finland 
DuoSet® ELISA Development System, human 
Decorin 
R&D Systems Wiesbaden-
Nordenstadt, Germany 
DyNAmo two-step SYBR Green qRT-PCR kit Finnzymes Oy Espoo, Finland 
MinElute® PCR Purification Kit QIAGEN GmbH Hilden, Germany 
Prolong Antifade Kit   
Proteome Profiler Array, Human Phospho-RTK R&D Systems Wiesbaden-
Nordenstadt, Germany 
RNeasy FFPE kit QIAGEN GmbH Hilden, Germany 
RNeasy Plus Mini kit QIAGEN GmbH Hilden, Germany 
Substrate Reagent Pack 
Color Reagent A (H2O2), Color Reagent B 
(Tetramethylbenzidine) 
R&D Systems Wiesbaden-
Nordenstadt, Germany 
SuperSignal West Femto Maximum Sensitivity 
Substrate 
Pierce, Thermo Fisher 
Scientific 
Bonn, Germany 
QIAquick Gel Extraction Kit QIAGEN GmbH Hilden, Germany 
Vectashield Mounting medium with DAPI Vector Laboratories Burlingame, CA, USA 
Vectastain ABC Kit Vector Laboratories Burlingame, CA, USA 
Venor® GeM – Mycoplasma Detection Kit Minerva Biolabs GmbH Berlin, Germany 
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10.5 Tools and machines 
Table 10-5: Overview of manufacturers and cities of employed tools and machines. 
 
Tool/Machine Manufacturer City 
Analytical balance XS 205 Mettler Toledo Giessen, Germany 
Biophotometer Eppendorf AG Hamburg, Germany 
Camera ProRes CT3 (Axiovert 135) Jenoptik Jena, Germany 
CASY-system Schärfe Systems Reutlingen, Germany 
Centrifuge Biofuge fresco Heraeus Holding GmbH Hanau, Germany 
Centrifuge Labofuge 400 Heraeus Holding GmbH Hanau, Germany 
CFX96 Real Time System and C1000 
Thermal Cycler 
Bio-Rad Helsinki, Finland 
ChemiSmart 5000 Peqlab Erlangen, Germany 
Confocal microscope TCS SP2 with 
laser and scanner 
Leica Microsystems Wetzlar, Germany 
Count-Down Timer Roth Karlsruhe, Germany 
ELISA-Reader Dynex Technologies Guernsey, Great Britain 
Engine Opticon system MJ Research, Inc. Waltham, MA, USA 
Fireboy plus Integra Biosciences Wallisellen, Switzerland 
Fluorescence lamp HBO 100 W Carl Zeiss AG München, Germany 
Fluorescence microscope Axioplan Carl Zeiss AG München, Germany 
Fluostar Optima BMG Labtech Offenburg, Germany 
Freezer -80 °C Sanoy München, Germany 
IKA-Magnetic stirrer RCT IKA-Labortechnik Staufen, Germany 
IKA-Shaker MTS4 IKA-Labortechnik Staufen, Germany 
Incubator BBD 6220 Heraeus Holding GmbH Hanau, Germany 
Laboratory pump KNF Neuberger Freiburg i. Br.; Germany 
Laboratory pump Chromaphor Duisburg, Germany 
Laminar airflow cabinet Holten LaminAir Allerød, Denmark 
Laser microdissection Carl Zeiss AG München, Germany 
Micro centrifuge Neolab Heidelberg, Germany 
Microscope Axiovert 135 Carl Zeiss AG München, Germany 
Microwave M690 Miele Gütersloh, Germany 
Multichannel pipet 20 – 200 µl 
                              100–1200 µl 
Rainin Giessen, Germany 
NanoDrop ND-1000 Finnzymes Oy Espoo, Finland 
PH-Meter Mettler Toledo Giessen, Germany 
Pipet 2µl/ 10µl/ 20µl/ 100µl/ 200µl/ 
1000 µl/ 5000µl 
Gilson Limburg-Offenheim, 
Germany 
Power Pac 300 Bio-Rad München, Germany 
SDS-PAGE Protean 3 Bio-Rad München, Germany 
Tender Cooker Nordic Ware Minneapolis, MN, USA 
Thermocycler PTC 200 Bio-Rad München, Germany 
Thermomixer comfort Eppendorf AG Hamburg, Germany 
Ultrasonic sound processor 50 H Dr. Hielscher GmbH Teltow, Germany 
Ultraturax T25 Janke & Kunkel, IKA-Labor-
technik 
Staufen, Germany 
UV detection system MWG Biotech Ebersberg, Germany 
Electronic stirrer Multipoint HP Variomag Daytona Beach, FL, USA 
Vortex-Genie 2 Scientific Industries Bohemia, NY, USA 
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10.6 Consumable supplies 
Table 10-6: List of used laboratory material, manufacturers and cities. 
 
Material Manufacturer City 
Cell scraper 24 cm TPP Trasadingen, Switzerland 
Centrifuge tubes, 15/50 ml Sarstedt Nümbrecht, Germany 
Crypure tubes, 1.6 ml Sarstedt Nümbrecht, Germany 
Culture flasks, 25/75 cm2 Sarstedt Nümbrecht, Germany 
Eppendorf tubes, 0.5/1.5/2.0 ml Sarstedt Nümbrecht, Germany 
Microplates, 96-well Greiner Bio-One GmbH Solingen, Germany 
Microplates maxisorp, 96-well Nunc Wiesbaden, Germany 
Multidish, 24-well Nunc Wiesbaden, Germany 
Nitrocellulose membran Whatman Dassel, Germany 
PAP pen Kisker Steinfurt, Germany 
Parafilm American National Can Chicago, IL, USA 
Pasteur pipettes, 150 mm Neolab Heidelberg, Germany 
Petri dishes, 35/60 mm Sarstedt Nümbrecht, Germany 
Pipette tips, 5000/1000/200/100/10 µl Rainin Giessen, Germany 
Feather disposable scalpel Pfm medical ag Köln, Germany 
Serological pipettes, 5/10/25/50 ml Sarstedt Nümbrecht, Germany 
Syringe filter, 0.2/0.45 Sarstedt Nümbrecht, Germany 
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10.7 Solutions 
Table 10-7: Overview and composition of used buffers and solutions. 
 
Solution Components 
APS for SDS-PAGE (10 %) 1 g APS in 10 ml ddH2O 
Separating gel buffer for SDS-PAGE 45.4 g Tris (1.5 M); total 250 ml, pH 8.8 
Calcium chloride (1 mM) 
 
0.20 g MgCl2 (1 mM)  
2.38 g HEPES (10 mM) 
1.8 g glucose (10 mM) 
pH 7.4 
10 x Laemmli buffer 30.28 g Tris (250 mM) 
Loading gel buffer for SDS-PAGE 15.2 g Tris (0.5 M); total 250 ml, pH 6.8 
1 x Buffer for proteinlysates 1.89 Tris (62.5 mM) 
5 g SDS (2 %) 
25 g Saccharose (10 %); total 250 ml, pH 6.8 
Bromophenol blue 0.75 g Tris (62.5 mM) 
2 g SDS (2 %) 
10 g Saccharose (10 %); total 100 ml, pH 6.8 
Ethidium bromide 10 mg/ml, use 1:10 dilution 
HEPES (10 mM):  
 
0.76 g EGTA (2 mM)  
30.45 g Potassium gluconate (130 mM) 
0.29 g NaCl (5 mM)  
pH 7.4 
KPBS 1.47 g KH2PO4 
8.59 g K2HPO4 
27 g NaCl 
total 500 ml, pH 7.4 
LKPBS 48.85 ml 0.02 M KPBS 
1 ml Normal serum 
0.15 ml Triton® X-100 
NPE-Buffer 4.4 g NaCl (150 mM) 
1.5 Pipes (10 mM) 
0.15 g EDTA (1 mM); total 500 ml, pH 7.2 
10 x Ponceau S  1 g Ponceau S in 500 ml 3 % trichloroacetic acid 
Protease inhibitorcocktail 10 µl PMSF (10 mg/ml) 
10 µl Aprotinin 
10 µl Leupeptin 
0.5 µl Sodium orthovanadate (1 M) 
1 ml 1 x Buffer for proteinlysates 
Sodium dodecyl sulfate (SDS) 1 g SDS in 10 ml ddH2O  
Solution A for immunohistochemistry (0.1 M) 21.01 g Citric acid 1 l ddH2O 
Solution B for immunohistochemistry (0.1 M) 29.41 g Trisodium citrate in 1 l  ddH2O 
5 x TBE buffer 54 g Tris 
27.5 Boric acid 
20 ml EDTA; total 1 l, pH 8.0 
20 x Tris-buffered saline (TBS) – Tween 20 116,8 g NaCl (2 M) 
12.1 g Tris 
10 ml Tween 20 (1 %); total 1 l, pH 7.5 
10 x Tranfer buffer 144.1 g Glycin (1.92 M) 
121.1 g Tris (250 mM) 
100 ml Methanol (10 %) 
1 ml SDS (0.01 %) 
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10.8 Proteome Profiler results 
Table 10-8: Summary of RTKs phosphorylated by DCN in HTPCs. 
Receptor family/Control RTK/Control Phosphorylation by DCN 
(+: yes; -: no) 
EGFR EGFR + 
EGFR ErbB2 + 
EGFR ErbB3 + 
EGFR ErbB4 + 
FGFR FGFR1 - 
FGFR FGFR2α - 
FGFR FGFR3 - 
FGFR FGFR4 - 
Insulin R Insulin R - 
Insulin R IGF-1R - 
Axl Axl - 
Axl Dtk - 
Axl Mer - 
HGFR HGFR + 
HGFR MSPR +/- 
PDGFR PDGFR-α +/- 
PDGFR PDGFR-β +/- 
PDGFR SCFR - 
PDGFR Flt-3 - 
PDGFR M-CSF-R - 
RET c-Ret - 
ROR ROR1 - 
ROR ROR2 - 
Tie Tie-1 - 
Tie Tie-2 + 
NGFR TrkA + 
NGFR TrkB + 
NGFR TrkC + 
VEGFR VEGFR1 - 
VEGFR VEGFR2 - 
VEGFR VEGFR3 - 
MuSK MuSK - 
EphR EphA1 - 
EphR EphA2 - 
EphR EphA3 - 
EphR EphA4 - 
EphR EphA6 + 
EphR EphA7 + 
EphR EphB1 +/- 
EphR EphB2 - 
EphR EphB4 - 
EphR EphB6 - 
Control (-) Mouse IgG1 - 
Control (-) Mouse IgG2A - 
Control (-) Mouse IgG2B - 
Control (-) Goat IgG - 
Control (-) PBS - 
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